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1 ABSTRACT 
Although coagulation is an essential process of hemostasis and wound healing, a number of 
studies published over the last two decades delineate an additional role of the intrinsic 
pathway of coagulation, also known as “contact system”, in the early innate immune 
response against bacterial infections. Thus, activation of the contact system on the surface of 
bacteria such as Streptococcus pyogenes (S. pyogenes) leads to the induction of the entire 
clotting cascade resulting in pathogen immobilization within the generated fibrin network. As 
coagulation factor XIII (FXIII) was identified as a key factor within this process, the overall 
objective of this study was the further investigation of the importance of FXIII during 
streptococcal infections in vitro and in vivo.  
Results obtained from in vitro clotting assays indicated that FXIII selectively influenced the 
entrapment of S. pyogenes bacteria of the serotype M1. The relevance of this FXIII-mediated 
entrapment mechanism for the host defense against S. pyogenes M1 was investigated in 
vivo using a murine model of streptococcal skin and soft tissue infection. Mice deficient in the 
expression of FXIII developed more severe infection and systemic complications after 
subcutaneous inoculation with S. pyogenes M1 than wild type animals as demonstrated by 
prolonged clotting times, elevated levels of the pro-inflammatory cytokine interleukin 6 (IL-6), 
increased bacterial dissemination and decreased survival. These results clearly illustrated a 
protective role of FXIII during S. pyogenes M1 infection. As a proof of principle, local 
reconstitution of FXIII-deficient mice with a human FXIII-concentrate (Fibrogammin®P) 
applied subcutaneously 1 h after S. pyogenes inoculation resulted in reduced systemic 
complications and an improved survival of infected FXIII-deficient mice.  
The results in this thesis also demonstrate the capacity of the M1 protein of S. pyogenes to 
inhibit the conversion of fibrinogen to fibrin during in vitro clotting, a mechanism that could 
help S. pyogenes bacteria of serotype M1 to counteract their immobilization within fibrin 
clots. Moreover, the A region of the streptococcal M1 protein was required for the inhibition of 
the fibrinogen conversion. However, it could be demonstrated that FXIII counteracted the M1 
protein-mediated inhibition of fibrinogen to fibrin conversion and supported the entrapment of 
S. pyogenes within the fibrin network. In the absence of FXIII, the lack of bacterial 
immobilization may explain the more extensive bacterial dissemination and infection severity 
observed in FXIII-deficient mice after subcutaneous inoculation with S. pyogenes M1.  
Results obtained in the context of this thesis support the concept of a therapeutic potential of 
FXIII and might lead to the development of novel antimicrobial strategies for the treatment of 
skin and soft tissue infections caused by S. pyogenes of serotype M1.  
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2 INTRODUCTION 
2.1 The genus Streptococcus 
Bacteria of the genus Streptococcus are Gram-positive organisms with a size of 0,6 to 1 µm. 
The origin of the name Streptococcus arises from the ancient Greek words “kókkos”, which 
characterizes the coccoid shape of these bacteria, and “streptós” that represents the 
property of these bacteria to arrange in chains or pairs (see Figure 2.1). Streptococci are 
non-motile bacteria that do not form endospores. The genus Streptococcus belongs to the 
family of Streptococcaceae and to the order of Lactobacillales. This may explain why 
streptococci generate their energy mainly by fermentative conversion of carbohydrates into 
lactate. Streptococci are facultative anaerobic and aerotolerant bacteria that grow best in 
nutrient-rich media.  
 
Figure 2.1: Electron microscopy image of Streptococcus pyogenes.  
Streptococcus pyogenes is the most prominent representative of the genus 
Streptocococcus. These coccoid pathogenic bacteria arrange in chains or pairs and 
can be coated with a hyaluronic acid capsule. This image was kindly provided by Prof. 
Dr. Manfred Rohde, Central Facility for Microscopy, HZI. 
The genus Streptococcus comprises numerous different species which can be classified by 
several methods. One of the first described methods was the classification of streptococci by 
their ability to lyse erythrocytes on blood agar, termed hemolysis (Brown, 1919; Taranta and 
Moody, 1971). Three types of hemolysis are distinguished: α-, β- and γ-hemolysis (see 
Figure 2.2). Alpha-hemolytic streptococci like Streptococcus pneumoniae (S. pneumoniae) 
mediate the oxidation of iron in the hemoglobin molecules within the erythrocytes and thus 
cause a change in absorbance maximum of hemoglobin. The result is a greenish zone 
around the bacterial colonies within the blood agar. Streptococcus pyogenes (S. pyogenes) 
belongs to the β-hemolytic bacteria that completely lyse erythrocytes, resulting in clear zones 
around bacterial colonies growing in blood agar. Streptococci that do not lyse erythrocytes at 
all are called γ-hemolytic (e.g. Streptococcus salivarius).  
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Figure 2.2: Types of hemolysis. 
Hemolysis can be classified into three types: the α-hemolysis mediated by S. 
pneumoniae (A), the β-hemolysis promoted by S. pyogenes (B) and γ-hemolysis 
observed for Streptococcus salivarius (C) (modified from https://www.studyblue.com/ 
notes/note/n/beta-hemolytic-strep/deck/3989611). 
The enormous antigenic variation among β-hemolytic streptococci allows their further 
classification into different serogroups following the scheme developed by Rebecca 
Lancefield in the 1930s. The Lancefield typing is based on the serological detection of 
antigenic differences of the C polysaccharide within the cell wall of β-hemolytic streptococci 
allowing their differentiation in Lancefield groups A to H and K to V (Lancefield, 1933). In the 
context of this thesis, most studies are focused on S. pyogenes, the most prominent 
representative of the genus Streptococcus. The C polysaccharide of S. pyogenes is 
composed of N-acetyl-β-D-glucosamine linked to a rhamnose polymer backbone (Zeleznick 
et al., 1963; Cunningham, 2000). Streptococcus dysgalactiae ssp. equisimilis (SDSE), an 
important representative of the group G streptococci (GGS), is also a subject of this thesis.  
2.2 Streptococcus pyogenes 
S. pyogenes or group A streptococcus (GAS) is a major human pathogen worldwide with an 
estimated global mortality comparable to infectious diseases caused by rotavirus, measles 
and Haemophilus influenzae type B (Carapetis et al., 2005). More than 1,78 million new 
cases of severe S. pyogenes infections causing more than 500 000 deaths are documented 
every year. Additionally, 111 million cases of streptococcal pyoderma and 616 million cases 
of S. pyogenes-mediated pharyngitis were reported annually (Carapetis et al., 2005).  
S. pyogenes exhibits great genetic and phenotypic variations that allow their further 
discrimination into serotypes by a molecular biology method called emm typing. This typing 
system is based on the DNA sequence analysis of the gene that encodes the hypervariable 
amino terminal (N terminal) part of the M protein (emm gene), an important surface protein of 
S. pyogenes. By using this method, more than 130 different S. pyogenes serotypes (Centers 
for Disease Control and Prevention, 2012) correlating with more than 220 emm genotypes 
have been differentiated up to now (Sanderson-Smith et al., 2014). This enormous diversity 
within the emm gene is thought to be a result of horizontal gene transfer by intragenic and 
A) B) C) 
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intergenic recombination within S. pyogenes species as well as with other streptococcal 
species like S. dysgalactiae and GGS (Carapetis et al., 2005; Simpson et al., 1992). 
2.2.1 Pathogenic potential of Streptococcus pyogenes  
S. pyogenes typically colonizes the mucosal surfaces and the skin and can be carried 
asymptomatically as a part of the human microbiota of the skin or respiratory tract (Tart et al., 
2007). Asymptomatic carriers represent the main reservoir for these bacteria because 
S. pyogenes mainly gets transmitted by respiratory droplets and direct person-to-person 
contact (Wong and Yuen, 2012). The factors influencing the development of a S. pyogenes 
infection include environmental, genetic, acquired host factors such as previous infections 
and the host immune status.  
 
Figure 2.3:  Entry and infections sites of Streptococcus pyogenes.  
S. pyogenes causes a broad range of infectious diseases ranging from mild, often self-
limiting infections to severe, life-threatening diseases. Rheumatic heart disease and 
glomerulonephritis are possible sequelae that can follow recurrent, non-treated 
S. pyogenes infections (modified after http://classroom.sdmesa.edu/eschmid/lecture 
16-microbio.htm and http://static.cosmiq.de/data/question/de/aae/80/aae8091052845d 
71ff7abe30c1cc9287_1_orig.jpg). 
The ability of S. pyogenes to cause a broad range of different diseases represents a special 
feature of these bacteria (see Figure 2.3). Hence, this versatile, human specific pathogen is 
responsible for mild, often self-limiting infections, but also for severe systemic, life-
threatening diseases. Accordingly, diseases caused by S. pyogenes can be divided into four 
classes: superficial infections, invasive infections, toxin-mediated infections and non-
suppurative complications (Jaggi and Shulman, 2006).  
2.2.1.1 Superficial infections 
Most frequently, the origin of superficial S. pyogenes infections is an infection of the mucosa 
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or epithelial membranes of the skin or upper respiratory tract causing pharyngitis, tonsillitis, 
Impetigo and pyoderma (Tart et al., 2007). S. pyogenes-mediated pharyngitis represents 
about 30 % of all acute infections in children between 5 and 15 years (Bisno, 1995). Typical 
clinical symptoms of this disease include sudden-onset fever combined with a sore throat 
causing an inflammation of the pharynx and tonsils (Walker et al., 2014). Pyoderma and its 
special variant Impetigo are S. pyogenes-mediated infections of upper layers of the skin 
affecting mostly the epidermis of the face and extremities (Bisno, 1996). 
2.2.1.2 Invasive infections 
Life-threatening, severe S. pyogenes infections are characterized by extensive tissue 
damage, vascular dissemination of bacteria and severe disease manifestation resulting in a 
high morbidity and mortality (Olsen et al., 2009). A typical starting point of invasive 
streptococcal infections might be a superficial infection after injury of the skin followed by 
invasion of the pathogen into deeper tissue. By transgression of anatomical barriers, 
S. pyogenes is able to disseminate through the blood stream and invade deeper muscle and 
skin layer causing invasive diseases, such as necrotizing faciitis (NF), bacteremia, cellulitis 
and sepsis. 
NF is associated with very high levels of human morbidity and high mortality rate due to the 
rapid progress of this disease (Olsen and Musser, 2010). The key mechanisms of this highly 
effective invasion of the host include the coordinated expression of virulence factors, tissue 
damage and vascular dissemination. Additionally, S. pyogenes can impair the host immune 
response and adapt very fast to the new host environment by rapidly adjusting its 
transcriptional response (Olsen et al., 2009). Also genetic and acquired host factors like 
antecedent viral infections influence NF pathogenesis (Olsen and Musser, 2010). The 
excessive tissue damage during NF is caused by tissue degradative enzymes produced by 
the invading bacteria as well as by the host immune cells such as neutrophils recruited in 
high numbers to the site of infection (Olsen and Musser, 2010). The main challenge for a 
successful treatment of NF is an early diagnosis. But as symptoms like fever, skin lesions, 
diarrhea, and toxemia are relative unspecific, an early diagnosis is not always feasible (Kaul 
et al., 1997). Also the treatment of NF is very difficult, and besides intravenous antibiotic 
therapy consisting of penicillin, clindamycin and vancomycin, often the surgical removal of 
infected tissue or amputations are required (Young et al., 2005). Furthermore, administration 
of intravenous polyclonal immunoglobulin (IVIG) was reported to have beneficial effects on 
the treatment of NF (Norrby-Teglund et al., 2005).  
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2.2.1.3 Toxin-mediated infections 
The streptococcal toxic shock syndrome (STSS) is an example of a toxin-mediated severe 
disease caused by S. pyogenes (Cone et al., 1987). STSS can be accompanied by NF and 
is mediated by bacterial superantigens belonging to the family of streptococcal pyrogenic 
exotoxins (SPEs) (Llewelyn and Cohen, 2002; Bisno et al., 2003). SPEs are potent immune-
stimulators which simultaneously can bind to the major histocompatibility complex class II 
(MHC-II) in antigen-presenting cells and to the T cell receptor (TCR) (Marrack and Kappler, 
1990). This leads to a massive activation of T cells and the concomitant excessive secretion 
of cytokines. The uncontrolled release of cytokines further triggers the activation of the 
complement system, coagulation and the fibrinolytic system that might result in hypertension 
and multi-organ failure, the two classical characteristics of STSS (Bisno et al., 2003). 
Scarlet fever is another toxin-mediated streptococcal disease that is caused by an infection 
of human pharynx with S. pyogenes strains secreting bacteriophage-encoded SPEs like 
SPE-A and –C (Walker et al., 2014). Typical symptoms of scarlet fever include deep red, 
finely papular, erythematous rash, the so-called “strawberry tongue” and exudative 
pharyngitis (Henningham et al., 2012). 
2.2.1.4 Post-infection sequelae 
Recurrent non-treated S. pyogenes-mediated superficial infections of the skin or pharynx can 
lead to post-infection immune sequelae like acute rhreumatic fever (ARF), rheumatic heart 
disease (RHD) and acute glomerulonephritis (APSGN). 
ARF represents the highest burden of all streptococcal sequelae, causing more than 23 300 
deaths per year (Carapetis et al., 2005) and is the main cause of RHD in children worldwide 
(Ellis et al., 2010). Typical clinical presentations of ARF comprise inflammation of the joints 
(arthritis), the heart (carditis), the central nervous system (chorea) and the skin (erythema 
marginatum) (Cunningham, 2000). The diagnosis and treatment of ARF are difficult due to 
the absence of clear symptoms in some patients (Veasy, 2001). RHD is a chronic, 
autoimmune disease caused by continuous damage of heart valves mediated by repeating 
recrudescence of ARF. RHD and ARF are major problems in indigenous populations such as 
the Aboriginal Australians and underdeveloped areas with restricted access to medical care 
due to poverty and overcrowding (Stollerman, 1997). The pathogenesis of ARF and RHD is 
complex and not completely understood but is influenced by host genetic as well as 
environmental factors. Autoimmunity might be caused by immunological cross-reaction of 
antibodies against streptococcal surface structures with host proteins. This phenomenon is 
called “molecular mimicry” and comprises auto-antibodies which recognize, for example, 
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streptococcal M protein as well as host myosin, two α-helical proteins (McNamara et al., 
2008; Kaplan and Suchy, 1964). 
Acute post-streptococcal glomerulonephritis (APSGN) is characterized by clinical symptoms 
such as edema, hypertension, urinary sediment abnormalities and reduced serum 
complement factor concentrations (Bisno, 2010). The pathogenesis is complex and includes 
the deposition of immune complexes, direct complement activation and cross-reactivity 
between antibodies against streptococcal antigens and host nephritic tissue (Friedman et al., 
1984; Cunningham, 2000; Henningham et al., 2012). 
2.2.2 Treatment and prevention of streptococcal mediated diseases 
Since the 1940s, the β-lactam antibiotic penicillin has been the treatment of choice against 
S. pyogenes infections (Pichichero and Casey, 2007; Stollerman, 1993). Surprisingly, these 
bacteria still remain penicillin-sensitive despite intensive use of penicillin to treat these 
infections during the last 50 years (Macris et al., 1998). Even in superficial, often self-limiting 
S. pyogenes infections, an antibiotic treatment is recommended to prevent the development 
of post-streptococcal immune sequelae and to reduce the infectivity and transmission to 
prohibit outbreaks (Bisno and Stevens, 1996). Although there is no penicillin resistance 
reported in S. pyogenes, some studies have reported failure of penicillin treatment of S. 
pyogenes-pharyngitis (Pichichero and Casey, 2007). Explanations for the penicillin tolerance 
of some strains include the co-existence with other β-lactamase-producing bacteria such as 
Bacillus fragilis, eradication of natural throat flora in vivo, carrier state, formation of biofilms 
as well as internalization of bacteria within epithelial host cells, a niche poorly penetrated by 
penicillin (Ogawa et al., 2011; Brook, 2007; Pichichero and Casey, 2007). In cases of 
penicillin incompatibility, macrolide antibiotics like erythromycin and clarithromycin, first 
generation cephalosporins as well as clindamycin are effective alternative agents against 
S. pyogenes (Walker et al., 2014).  
Despite their exquisite antibiotic-sensitivity, a resurgence of severe invasive S. pyogenes 
infections has been observed worldwide since the 1980s. Occurrence of dominant 
S. pyogenes clones, like M1T1, through horizontal gene transfer of new toxin-encoding 
mobile genetic elements caused these current developments (Aziz et al., 2005; Beres and 
Musser, 2007). The S. pyogenes clone M1T1, which is also subject of this study, is 
distributed worldwide and represents the most frequently isolated serotype in the western 
world (Aziz and Kotb, 2008; Cleary et al., 1992). M1T1 acquired a chromosomal DNA region 
of 36 kb which encodes the DNase SdaI and the superantigen SPE-A, probably responsible 
for the effective pathogenicity of this clone (Henningham et al., 2012). 
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Persistent S. pyogenes infections and post-streptococcal immune sequelae are severe 
problems, especially in geographical regions with a poor access to high standard healthcare 
(Henningham et al., 2012). Effective control and eradication of S. pyogenes-mediated 
diseases can be only be achieved by a safe and effective vaccine. But to date, an 
appropriate vaccine is not available, despite of extensive research. Major difficulties in 
S. pyogenes vaccine development result from serotype diversity (McMillan et al., 2013), 
great antigenic variation within certain serotypes (Gillen et al., 2002), differences in 
geographical distribution of serotypes (Steer et al., 2009) and the major problem of 
S. pyogenes antigens to potentially cause autoimmunity by cross-reactive antibodies 
recognizing human tissue structures (Kirvan et al., 2003).  
In the past, different S. pyogenes antigens including cell wall- or membrane-anchored and 
secreted molecules as well as group A carbohydrate were investigated for their vaccine 
potential (Cole et al., 2008). However, vaccine research has mainly focused on the potential 
of the major virulence factor, the streptococcal M protein as suitable vaccine. Although in 
vivo studies using whole M protein-based vaccines showed effective protection against 
S. pyogenes-mediated pharyngitis, protection was accompanied by high auto-immunological 
potential (D’Alessandri et al., 1978; Fox et al., 1973; Polly et al., 1975; Massell et al., 1969). 
For this reason, research concentrated on the non-cross reacting amino (N) terminal, type 
specific part of the M protein. To date, two promising, so far safe and immunological active 
vaccine candidates are under investigation in different phases of clinical trials: a hexavalent 
and a multivalent preparation containing 6 and 26 N-terminal M protein fragments of different 
serotypes, respectively (Dale et al., 1999; Kotloff et al., 2004).  
2.2.3 Virulence of Streptococcus pyogenes 
The highly versatile pathogen S. pyogenes causes a broad range of clinical manifestations at 
various infection sites. The basis for this remarkable virulence relies in a huge repertoire of 
different virulence factors (see Figure 2.4). 
The first step of a S. pyogenes-mediated infection includes the bacterial adhesion to the host 
tissues, which is generally mediated by streptococcal surface structures such as lipoteichoic 
acid (LTA), streptococcal M protein, hyaluronic acid or fibronectin binding proteins (FBP) that 
bind to specific receptors of the host cell (reviewed by Cunningham, 2000). In 1999, 
Courtney and colleagues described a two-step-model of streptococcal adhesion: the first 
step involves the interaction between LTA with host surface structures leading to a relatively 
weak adhesion; the second step involves a high-avidity adherence and tissue specificity 
mediated by the M protein and FBP (Courtney et al., 1999; Hasty and Courtney, 1996).  
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Figure 2.4:  Virulence factors of S. pyogenes  
S. pyogenes comprises a remarkable collection of surface-associated and secreted 
virulence factors that mediate its great virulence and capacity to induce a broad range 
of different diseases (modified after Mitchell, 2003).  
Traditionally, S. pyogenes is described as a classical extracellular pathogen, however, it can 
internalize within human cells. The capacity of S. pyogenes to invade human epithelial cells 
was demonstrated by LaPenta and colleagues in 1994 (LaPenta et al., 1994). High 
frequently invasion of S. pyogenes requires different invasins like the streptococcal M protein 
and/or FBPs (Fluckiger et al., 1998). Internalization of S. pyogenes has been proposed to be 
an important step during its pathogenesis since it can be possibly used by the bacterium to 
escape the antimicrobial effect of penicillin treatment as well as the host immune defense 
mechanisms (Cunningham, 2000; LaPenta et al., 1994). 
Host colonization by S. pyogenes involves a rapid adaptation to the hostile environment as 
well as the evasion of the host immune components such as avoiding complement activation, 
impairing recruitment of neutrophils and inhibiting phagocytosis (Bisno et al., 2003). These 
processes are also mediated by streptococcal virulence factors such as the M protein, the 
hyaluronic acid capsule as well as the streptococcal inhibitor of complement-mediated lysis 
(SIC). 
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During the last step of infection, S. pyogenes tries to spread and disseminate within the host 
by damaging host tissues via release of streptococcal toxins like SPE-A and –C. Bacterial 
invasion and migration through tissue barriers is also enabled by recruitment of plasminogen 
via plasminogen-binding proteins such as enolase, streptokinase and glyceraldehyd 
dehydrogenase (Cunningham, 2000).  
2.2.3.1 Surface-associated virulence factors 
The surface of S. pyogenes is covered with a great repertoire of virulence factors that 
contribute to bacterial attachment, internalization and colonization of the host.  
2.2.3.1.1 Streptococcal M protein 
The M protein is the best studied and probably the most important virulence factor of 
S. pyogenes. The M protein contributes to attachment and invasion into host cells as well as 
to bacterial persistence during infection. The streptococcal M protein is a surface-associated 
protein that is anchored to the cell membrane by a LPXTG motif, traverses the complete 
bacterial cell wall and appears on the cell surface in a fibrillar, hair-like structure (Fischetti, 
1991). It comprises two identical polypeptide chains that form an alpha-helical coiled-coil 
configuration (Hollingshead et al., 1987; McNamara et al., 2008). Each polypeptide chain 
contains four repeat regions (A, B, C and D), which differ in size due to variation in the 
number of certain repeats and their amino acid sequence (see Figure 2.5; Fischetti, 1989). 
The carboxy terminal (C terminal) part of the M protein contains the C and D repeats as well 
as a proline-glycine-rich and a hydrophobic membrane spanning domain. The amino acid 
sequence of the C and D repeats is highly conserved among S. pyogenes serotypes and 
binds factor H and human serum albumin. The central M protein domain is semi-variable and 
contains the B repeats, which exhibit fibrinogen-binding activity (Ringdahl et al., 2000). The 
sequence of the extracellular N terminal domain is hypervariable and represents the basis for 
the serological Lancefield classification and molecular biological “emm-typing”. The resulting 
antigenic variation between S. pyogenes serotypes might be a selective advantage to avoid 
antibody recognition. Interaction partners of the N terminal domain are factor H and factor H 
like proteins, C4 binding protein (C4BP), plasminogen, immunoglobulin (Ig) A and G and 
fibronectin (Fischetti, 2000; Cue et al., 2001). 
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Figure 2.5:  Structure of the streptococcal M1 protein. 
The structure of the streptococcal M1 protein is shown schematically (right) and as 
structure model (left). The figure shows the M1 protein encompassing a single A 
repeat domain (yellow), three B repeat domains (green), a small S domain (violet), 
three C repeat domains (blue) and a single D repeat domain (red). M proteins are 
anchored to the bacterial cell membrane and traverse the whole bacterial cell wall 
(modified after McArthur and Walker, 2006). 
The M protein was shown to mediate the bacterial adherence to HEp-2 tissue culture cells 
via fibronectin (Courtney et al., 1986; Sanford et al., 1982). The attachment of S. pyogenes 
to human epithelial and skin fibroblasts is also mediated by the M protein through the binding 
to cellular glucosaminoglycans or components of the extracellular matrix (ECM) (Frick et al., 
2003). Additionally, the streptococcal M protein is involved in biofilm formation by complex 
formation with LTA (Lembke et al., 2006; Courtney et al., 1986).  
As mentioned above, S. pyogenes can also internalize within eukaryotic cells. One strategy 
for streptococcal internalization comprises the binding of fibronectin by the M protein A and B 
repeat regions and the interaction of fibronectin with α5β1-integrin that causes actin 
cytoskeleton rearrangements leading to bacterial uptake (Dombek et al., 1999). Another 
internalization strategy involves the activation of intracellular signaling pathways by the M 
protein or M protein-fibronectin complexes (Purushothaman et al., 2003). Additionally, M 
proteins can mediate bacterial internalization by targeting the keratinocyte surface cofactor 
CD46 (Rezcallah et al., 2005).  
The capacity of S. pyogenes bacteria to survive in human blood is known for a long time and 
could be explained by their ability to avoid phagocytosis-mediated killing by interfering with 
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the human complement pathway (Oehmcke et al., 2010). Phagocytosis resistance of 
S. pyogenes is mediated by several mechanisms including the inhibition of complement 
activation. This can be mediated by binding host serum components such as C4BP, a 
regulator of the classical complement pathway (Karin Berggaard et al., 2001; Morfeldt et al., 
2001). The binding of factor H and factor H-like proteins by the streptococcal M protein 
prohibits the activation of the alternative complement pathway. Another strategy to resist 
phagocytosis consists in the binding of the plasma protein fibrinogen by the M protein. 
S. pyogenes bacteria covered with fibrinogen are not recognized by the complement factor 
C3-binding protein that activates the alternative complement pathway (Whitnack et al., 1983; 
Horstmann et al., 1992).  
2.2.3.1.2 M like Proteins 
M like proteins are Ig-binding proteins encoded by the emm gene superfamily (Cunningham, 
2000). The overall structure of these proteins is quite similar to that of the M protein of 
S. pyogenes but differs in the types of repeat regions (Bisno et al., 2003). The ability of M like 
proteins to bind a broad range of host proteins like IgA and IgG, albumin, fibrinogen and 
plasminogen as well as their contribution to phagocytosis resistance represents another 
similarity to S. pyogenes M proteins (Podbielski et al., 1996; Ji et al., 1998). To date, more 
than 20 genes belonging to emm gene superfamily have been identified that share more than 
70 % sequence identity at their 5´ends encoding the cell-associated region of the M protein 
molecule (Hollingshead et al., 1993). Representative proteins of emm like genes are for 
example the fibrinogen-binding protein of SDSE (FOG protein) as well as the M-related 
protein (Mrp), Emm and Enn (Courtney et al., 2006). 
2.2.3.1.3 Hyaluronic acid capsule 
Many S. pyogenes isolates are covered with a capsule containing the high molecular weight 
polymer, hyaluronic acid (HA). HA consists of repeating residues of glucuronic acid and N-
acetylgucosamin (Stoolmiller and Dorfman, 1969). HA synthesis is regulated by an operon 
containing three genes, hasA, hasB and hasC, representing the gene sequences for 
hyaluronate synthase, UDP-glucose dehydrogenase and UDP-glucose pyrophosphorylase, 
respectively (Crater et al., 1995; Dougherty and Van de Rijn, 1992). The degree of 
encapsulation varies among different S. pyogenes serotypes and is directly connected to 
their phagocytosis resistance capacity (Wessels and Bronze, 1994). Thus, acapsular 
isogenic mutant strains show a 100-fold decrease in bacterial virulence (Wessels et al., 
1991). In phagocytosis resistance, HA capsule represents a physical barrier to prevent the 
recognition of opsonic complement proteins on the bacterial surface by phagocytes 
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(Cunningham, 2000). By targeting CD44 molecules on the surface of pharyngeal epithelial 
cells, the HA capsule also functions as an effective adhesin (Schrager et al., 1998).  
2.2.3.1.4 Lipoteichoic acid  
Lipoteichoic acid (LTA) is described as a first step adhesin targeting fibronectin and epithelial 
cells. Hydrophobic interactions allow close contact between the pathogen and host cells 
which represent the basis of high affinity binding in the second step of adhesion (Hasty et al., 
1992). LTA is an amphiphatic molecule which accounts for approximately 60% of adhesion in 
epithelial cells (Hasty and Courtney, 1996). 
2.2.3.1.5 Fibronectin binding proteins 
A common attachment and invasion strategy used by S. pyogenes represents the binding of 
ECM proteins like fibronectin, collagen and laminin by streptococcal virulence factors (Walker 
et al., 2014). Thus, fibronectin-binding proteins (FBPs) are important for the adherence to 
host cells in throat and skin. Fibronectin is a dimeric glycoprotein which contains a RGD 
(arginin-glycin-aspartate) motif that is recognized by host cell surface α5β1 integrin (Singh et 
al., 2010). Therefore, streptococcal FBPs function as “bridging” molecules between the 
bacteria and host cell surfaces. The binding of α5β1 integrin activates intracellular signaling 
pathways that cause the rearrangement of actin cytoskeleton and allows the bacterial uptake 
(Walker et al., 2014). 
Streptococcal fibronectin-binding protein I (SfbI/PrtI) (Talay et al., 1992; Hanski and Caparon, 
1992), SfbII/Serum opacity factor (SOF) (Kreikemeyer et al., 1995), FBP 54 (Hasty and 
Courtney, 1996) and streptococcal M proteins belong to the most important examples of 
streptococcal FBPs (Bisno et al., 2003). SfbI is the most prominent FBP and plays an 
important role in adhesion and internalization into non-phagocytic cells like respiratory 
epithelial cells and cutaneous Langerhans cells (Hanski et al., 1992; Okada et al., 1995; 
Guzmán et al., 1999). Expression of SfbI is environmentally regulated by oxygen (O2) and 
carbon dioxide (CO2). 
2.2.3.1.6 C5a peptidase 
Another cell wall anchored streptococcal virulence factor is the proteolytic enzyme C5a 
peptidase. This 130-kDa serine protease is responsible for the cleavage of C5a, a 
complement derived chemotaxin, at its binding site for PMNs. This interaction leads to an 
inhibition of PMN recruitment to the site of infection and thus reduced clearance of the 
invading pathogen (Cleary et al., 1992; Ji et al., 1996; Wexler et al., 1985). 
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2.2.3.2 Secreted virulence factors 
In addition to the surface-associated virulence factors, S. pyogenes bacteria secrete 
numerous extracellular products that contribute to their pathogenesis. 
2.2.3.2.1 Haemolysins 
Streptolysin O (SLO) is a haemolysin produced by S. pyogenes strains that belongs to the 
family of cholesterol dependent cytolysins. SLO possesses lytic activity against all cells that 
contain cholesterol in their cytoplasmic membrane like PMNs, platelets and macrophages. It 
is irreversibly inhibited by cholesterol and O2-labile (Mitchell, 2003; Bisno et al., 2003).  
Streptolysin S (SLS) is another haemolysin produced by S. pyogenes, especially during 
growth in the presence of serum and molecules like albumin and α-lipoprotein. SLS can be 
intracellular, cell surface bound or extracellular and is one of the most potent cytolysins 
which is delivered to target cells by direct contact with the bacterium (Bisno et al., 2003; Ofek 
et al., 1990). SLS is thermolabil but not influenced by O2. 
SLO and SLS are important virulence factors during the pathogenesis of NF by effectively 
damaging cell membranes of PMNs, platelets and subcellular organelles. Often both types of 
haemolysins are produced by the same S. pyogenes isolates (Bisno et al., 2003). 
2.2.3.2.2 Streptococcal pyogenic exotoxins  
Streptococcal pyogenic exotoxins (SPEs) represent a family of proteins which lead to 
pyogenicity and have superantigenic effects on the immune system (Alouf, 1980). The 
special feature of these superantigens is their ability to activate much higher amounts of T 
cells than conventional antigens (Kotzin et al., 1993; Kappler et al., 1989). This effect is 
mediated by their property to simultaneously bind T cell receptors and MHC II molecules on 
antigen presenting cells that results in the stimulation of T cell proliferation and the con-
comitant release of high amounts of inflammatory cytokines such as tumor necrosis factor α 
(TNFα), interleukin (IL) 1β and IL-2 (Fast et al., 1989; Herman et al., 1991; Kotb, 1995).  
2.2.3.2.3 SPE-B 
SPE-B, also called streptococcal proteinase, was long thought to be a streptococcal super-
antigen, but meanwhile it has been demonstrated that SPE-B solely exert proteolytical 
activity. SPE-B is a very potent cysteine protease produced by almost all S. pyogenes strains 
but in different amounts (Kapur et al., 1993; Musser et al., 1993). SPE-B is an important 
virulence factor of S. pyogenes during invasive diseases like NF contributing to tissue 
damage by cleavage of human Ig, vitronectin and other host proteins and generation of 
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biologically active molecules like IL-1β, kinins and histamine (Collin and Olsén, 2001; Kapur 
et al., 1993). 
2.2.3.2.4 Streptokinase 
The fibrinolytic activity of S. pyogenes was already observed in 1933 (Tillett and Garner, 
1933) and the responsible bacterial factor was later named Streptokinase (SK) (Green, 
1948). The property of S. pyogenes to dissolve a fibrin network represents a logical strategy 
to avoid the early human immune response that leads to fibrin deposition to confine the 
bacteria. By fibrin deposition, the infection site is targeted for further immune responses 
(Levi, 2004). SK is a 46 kDa protein consisting of three similar domains (α, β, γ) that are 
separated by two loops (Hoffmeister et al., 1998). The main function of SK is the activation of 
human plasminogen. But, in contrast to human plasminogen, activators like urokinase or 
tissue plasminogen activator (uPA and tPA), SK has no intrinsic enzymatic activity. The SK 
proteolytic activity is generated by complex formation with human plasminogen (Reddy and 
Markus, 1972). Active plasminogen-SK complexes convert other plasminogen molecules to 
plasmin, a serine protease that is a major component of the human fibrinolytic system 
(Lottenberg et al., 1994). In this process, SK serves as a “communication tool” between the 
bacteria and the host for establishing a proteolytic environment that supports the virulence 
and invasiveness of S. pyogenes (Cook et al., 2012). 
2.2.3.2.5 Streptococcal inhibitor of complement-mediated lysis 
Another virulence factor of S. pyogenes that was identified in the AP1 strain of serotype M1 
represents the streptococcal inhibitor of complement-mediated lysis (SIC) (Akesson et al., 
1996). SIC interferes with the complement-mediated lysis of erytrhocytes by binding 
regulatory complement proteins such as clusterin and histidin-rich glycoprotein that interact 
with the membrane attack complex (Akesson et al., 1996; Fernie-King et al., 2001). The role 
of SIC in streptococcal virulence was demonstrated by impaired capacity of isogenic mutant 
strains lacking the SIC protein to colonize mice in comparison to wild type bacteria (Lukomski 
et al., 2000). 
2.3 The human coagulation system  
2.3.1 Coagulation during hemostasis 
Coagulation is a part of blood hemostasis, a vital process to prevent the loss of life-
threatening amounts of blood after injury of blood vessels. Therefore, hemostasis is one of 
the fastest tissue repair systems, which is activated within seconds after vascular injury and 
a necessary condition for wound healing (Versteeg et al., 2013). The primary step of cellular 
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hemostasis comprises platelet aggregation at the site of injury and the formation of a loose 
platelet plug, while the coagulation process per se represents the secondary, or plasmatic, 
hemostasis which ensures plug stabilization by formation of a stable fibrin network. Beside, 
preventing the excessive loss of blood cells and plasma proteins, rapid wound healing also 
avoids the entrance of pathogenic microorganisms (van der Poll and Herwald, 2014).  
 
Figure 2.6:  Schematic representation of coagulation cascade and fibrinolysis. 
The blood coagulation is initiated by an extrinsic (grey) and an intrinsic (red) pathway 
of coagulation which both finally lead to the activation of the common pathway of 
coagulation (blue). To ensure hemostasis, the fibrinolytic system (green) mediates the 
degradation of fibrin clots. Coagulation factors are indicted with “F”, the addition “a” 
represents the active form, uPA/tPA: urokinase/tissue plasminogen activator; HK: high 
molecular weight kininogen (Loof, Deicke and Medina, 2014). 
The blood coagulation cascade is initiated by an intrinsic or an extrinsic pathway, both 
leading to the activation of the common pathway (see Figure 2.6). The common pathway is 
initiated by the activation of factor X (FX) which further activates prothrombin to thrombin. 
Thrombin then catalyzes the conversion of fibrinogen to fibrin which subsequently forms a 
fibrin network by the clustering of fibrin monomers into fibrils. Afterwards, fibrin fibrils are 
stabilized by thrombin-activated factor XIII (FXIII). During thrombin activation, early 
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generated thrombin induces the feedback activation of factor V (FV) and factor VIII (FVIII) 
(Brummel et al., 2002). 
2.3.1.1 Extrinsic coagulation pathway 
Tissue factor or tissue thromboplastin (TF) is the key activator of the extrinsic coagulation 
pathway (see Figure 2.6). This membrane-spanning glycoprotein is constitutively expressed 
on many extravascular cells like blood vessel surrounding fibroblasts, pericytes and epithelial 
cells (Breitenstein et al., 2010; Wilcox et al., 1989). Besides its main function in activation of 
coagulation, TF also mediates several inflammatory reactions by inducing the release of 
cytokines, chemokines and adhesion factors (Åberg and Siegbahn, 2013; Chu, 2005; 
Srinivasan and Bogdanov, 2012). After injury and damage of vascular endothelial cells, TF is 
exposed to the blood plasma and forms a catalytic complex with factor VII (FVII), which 
further activates factor IX (FIX) and FX (see Figure 2.6; Delvaeye and Conway, 2009). FX 
leads to the activation of thrombin on the platelet surface and the induction of the common 
coagulation pathway that finally promotes further coagulation and thrombus formation.  
2.3.1.2 Intrinsic coagulation pathway  
The intrinsic pathway of coagulation, also known as the contact system, includes four factors: 
the proteases FXII, FXI and plasmakallikrein (PK) as well as the non-enzymatic co-factor 
high molecular kininogen (HK) (see Figure 2.6; Frick et al., 2007). Under physiological 
conditions, these factors circulate as zymogens in the blood or are assembled to endothelial 
cells, platelets or PMNs (Colman and Schmaier, 1997). Their activation is induced by 
endothelium changes from anti- to pro-coagulant status e.g. after injury. Contact factors such 
as FXII assemble on negatively charged surfaces like kaolin, glass, dextrane sulfate, 
biological material like DNA, RNA and collagen as well as the surfaces of gram-positive and 
gram-negative bacteria (Maas et al., 2011; Ben Nasr et al., 1997; Herwald et al., 1998; 
Sriskandan et al., 2000). By binding to a bacterial surface, FXII is autocatalytically activated 
into FXIIa which in turn activates PK and FXI, both anchored to the bacterial surface by HK 
(see Figure 2.6; Ben Nasr et al., 1995). FXI triggers the common pathway of coagulation by 
activating FIX and FX whereas PK cleaves HK which leads to the generation of the 
proinflammatory and vasoactive peptide bradykinin (BK) (Joseph and Kaplan, 2005; Bhoola 
et al., 1992). 
2.3.1.3 Fibrinogen and Fibrin 
The formation of a stable fibrin clot is the critical step of the coagulation process that ensures 
wound closure and prevents the invasion of pathogens. Monomeric fibrinogen is a soluble 
precursor protein consisting of two α-, two β- and two γ-polypeptide chains building up a 
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complex fibrous heterohexamer (αA, βB, γ2) with a total molecular weight of 340 kDa 
(Weisel, 2005; Doolittle, 1983). The six polypeptide chains are intramolecularly linked by 29 
disulfide bonds (Henschen and McDonagh, 1986). The complex fibrinogen molecule contains 
a central, globular E domain, built by the N terminal ends of the α-, β-, and γ-chain, as wells 
as two globular D domains (see Figure 2.7). The fibrinogen D domains are located at both 
ends of a fibrinogen molecule and contain the C terminal ends of the α-, β-, and γ-subunits 
(see Figure 2.7). The external globular D domains are connected with the central E domain 
by triple-stranded α-helical coiled-coiled rods (reviewed by Weisel, 2005).  
 
Figure 2.7: Formation of a fibrin clot during coagulation. 
Fibrinogen consists of two α (orange), two β (blue) and two γ polypeptide chains (pink) 
building up two external globular D domains and a central globular E domain 
connected by α-helical coiled-coiled rods. The conversion of fibrinogen to fibrin is 
catalyzed by thrombin and induces the cleavage of fibrinopeptides (1). Fibrin 
polymerization is mediated by interactions between C terminal “knobs” and N terminal 
“holes” of the β- and γ-subunits (2) (Freeman, 2012). 
During clot formation, soluble monomeric fibrinogen molecules are converted into fibrin by 
the thrombin-mediated enzymatic cleavage of four arginin-glycine bonds within the E domain 
releasing the fibrinopeptides A and B (FPA and FPB) from the N termini of both α- and β-
subunits of fibrinogen (see Figure 2.7; Blombäck et al., 1978). Although FPA and FPB 
constitute less than 2% of the total molecular weight, the cleavage has profound structural 
consequences that allow fibrin polymerization (Yang et al., 2000). The newly formed N 
termini of the α- and β-chain within the central E domain expose new binding sites called 
“knobs”. Corresponding “holes” are exposited by β- and γ-chains C termini. The binding of 
“knobs” and “holes” allows the spontaneous assembly of fibrin molecules into protofibrils, 
which further aggregate three-dimensional fibers. This process is mediated by intermolecular 
interactions between different fibrin molecules (reviewed by Mosesson, 2005; Weisel, 2005). 
During fibrin polymerization, γ-dimers are generated by assembly of two γ-chains of different 
fibrin molecules. Furthermore α-polymers are generated by association of several α chains 
(Mosesson, 2005; Francis and Marder, 1987).  
„knobs“ „holes“ 
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In addition to the important function of fibrinogen/fibrin during coagulation, these molecules 
exert additional functions in wound healing, inflammation and angiogenesis by interaction 
with a broad range of molecules like fibronectin, albumin, thromboplastin, von Willebrand 
factor, fibroblasts and vascular endothelial growth factor (reviewed by Weisel, 2005). 
2.3.1.4 Fibrinolysis  
To prevent blood loss and ensure blood fluidity, hemostasis is a tightly regulated process 
(Kolev and Machovich, 2003). Fibrinolysis represents one part of these regulation processes 
that is responsible for the sequential degradation of fibrin clots into distinct degradation 
products (Cesarman-Maus and Hajjar, 2005; Walker and Nesheim, 1999). Fibrinolysis and 
coagulation are simultaneously activated whereas fibrinolysis operates more slowly. The 
major fibrinolytic protease plasmin is generated from the zymogen plasma protein 
plasminogen by tPA and uPA as well as by FXIIa and PK, linking the contact system to 
fibrinolysis (see Figure 2.6; Maas et al., 2011). The fibrinolytic system is regulated by tPA 
and uPA as well as by plasminogen activation inhibitors like PAI-1, α-antiplasmin or TAFI 
(thrombin-activatable fibrinolysis inhibitor) (reviewed by Longstaff and Kolev, 2015 and van 
der Poll and Herwald, 2014). 
2.3.2 Coagulation as a part of innate immunity against streptococcal 
infections  
The hemostasis, including coagulation, and the host innate immune system have been 
viewed as two entirely separated systems in the past. However, during the last two decades 
a growing body of evidence has been provided demonstrating that coagulation also 
participates in the early host innate immune defense against pathogens. It was demonstrated 
that coagulation plays an active role in the containment and elimination of invading 
pathogens, including S. pyogenes (Loof et al., 2010; Esmon et al., 2011; Loof et al., 2011a; 
Wang et al., 2010). It was also shown that coagulation activates several innate immune 
mecha-nisms including the release of antimicrobial peptides (AMPs) from platelets, 
generation of AMP during clotting, induction of the cellular immune response by recruitment, 
attachment and activation of phagocytes as well as the activation of pro- and anti-
inflammatory reactions (Frick et al., 2006; Kirschenbaum et al., 2004; Shpacovitch et al., 
2008). 
2.3.2.1 Innate immune response against Streptococcus pyogenes  
The fundamental basis of an effective defense against invading pathogens includes the 
cooperation of various chemical, physical, enzymatic and cellular components of the immune 
system. Traditionally, the mammalian immune system is classified into the rapid, but rather 
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unspecific, innate immune response and the highly specialized, but more slowly acting, 
adaptive immune response. Whereas current literature provides a general overview about 
the host innate immune mechanisms against S. pyogenes infections, the role of the adaptive 
immune response including highly specialized T and B lymphocytes as well as highly specific 
antibodies is less well studied (Fieber and Kovarik, 2014). 
The initiation of the host immune response to fight S. pyogenes requires the recognition of 
the invading bacteria through pathogen-associated molecular patterns (PAMPs), which are 
conserved molecules or structures within pathogens that are not present in the host. The 
innate immune system is activated upon recognition of PAMPs by the corresponding host 
pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs). Recognition leads 
to the induction of intracellular signaling pathways leading to the activation of transcription 
factors such as NFκB and the production of chemokines and cytokines involved in the 
recruitment of immune cells (see Figure 2.8) (Medzhitov et al., 1998; Kawai and Akira, 2010). 
Several studies using murine S. pyogenes infection models identified the signaling adaptor 
MyD88 as a key component of the initiation of the immune defense and inflammatory 
response against S. pyogenes-mediated infections (Loof et al., 2010, 2008).  
The innate immune response against S. pyogenes is complex and includes the recruitment 
and activation of PMNs, macrophages and dendritic cells (DCs) (Fieber and Kovarik, 2014; 
Goldmann et al., 2004; Loof et al., 2007; Mishalian et al., 2011). The complete repertoire of 
innate immune components and their relevance are not completely understood today. 
Nevertheless, studies using murine S. pyogenes infection models indicate the requirement of 
macrophages to limit bacterial spreading within the host and to ensure the survival of 
infected mice (Goldmann et al., 2004). Macrophages are innate immune cells which are 
important for pathogen recognition and elimination by phagocytosis, for the induction of a 
local inflammatory response as well as for activation of the adaptive immunity by antigen 
presentation on MHC II molecules (Cavaillon and Adib-Conquy, 2005). Macrophages are the 
major producer of TNFα and simultaneously are highly responsive to this cytokine 
(Parameswaran and Patial, 2010). TNFα is also secreted by DCs (Loof et al., 2008), which 
are highly specialized antigen-presenting cells that mainly contribute to antigen capture and 
processing as well as the stimulation of other immune functions by secretion of cytokines. 
Other essential innate immunity components against S. pyogenes-mediated infections are 
PMNs which migrate from the blood stream to infected tissues after infection stimuli. PMNs 
mainly control bacterial infections by degranulation, phagocytosis, generation of massive 
amounts of reactive oxygen and nitrogen species, the release of inflammatory mediators like 
AMP, hydrolytic and proteolytic enzymes as well as limiting the dissemination of invading 
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pathogens by neutrophil extracellular traps (NETs) (Amulic et al., 2012; Borregaard et al., 
2007; Brinkmann et al., 2004).  
 
Figure 2.8:  Mechanisms of S. pyogenes recognition and activation of the innate immune 
response. 
Invading S. pyogenes bacteria are recognized by TLRs which activate intracellular 
signaling via the MyD88 adaptor molecule. This leads to the generation of TNF, IFN-β 
and IL-1β in the nucleus and to the secretion of other pro-inflammatory cytokines and 
chemokines recruiting macrophages and neutrophils. TLR13 is involved in the 
recognition of streptococcal 23s rRNA. Lysosomal TLR9 mediates killing of GAS by 
generating reactive oxygen and nitrogen species. Type I IFN regulates infiltration of 
neutrophils by a process which is only poorly understood, to date (Fieber and Kovarik, 
2014). 
2.3.2.2 Bacterial entrapment within fibrin networks 
In addition to previously described pro-inflammatory innate immune functions (see section 
1.2.2), coagulation is also involved in the containment and elimination of S. pyogenes (Loof 
et al., 2011b). Activation of the intrinsic pathway of coagulation by S. pyogenes is mediated 
by the binding and activation of FXII on the bacterial surface that was already decribed in 
section 2.2.1.2. Beside FXII, also FV, FXI, HK and fibrinogen assemble on S. pyogenes 
surface by interactions with bacterial surface proteins such as M proteins (Herwald et al., 
2003b). The assembly of contact factors leads to the activation of the entire clotting cascade 
including the activation of prothrombin, fibrinogen and FXIII and leading to the formation of a 
fibrin clot (Loof et al., 2011b). During clotting, S. pyogenes is entrapped and immobilized 
within the fibrin network where bacteria are confined and their dissemination and spreading 
within the host is prevented (see Figure 2.9; Loof et al., 2011b; Sun et al., 2004; Sun, 2006; 
Matsuda et al., 2007). In addition to the confinement of bacteria at the site of infection, the 
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coagulation system also exerts bactericidal activities. Several AMPs are generated during 
coagulation including fragments of the D3 and D5 domain of HK, host defense peptides 
generated from thrombin as well as fibrinogen-derived AMPs (Frick et al., 2006; Nordahl et 
al., 2005; Papareddy et al., 2010; Påhlman et al., 2013). Additionally, Loof and colleagues 
reported cell membrane disruption and bacterial killing within fibrin clots (Loof et al., 2011b). 
 
Figure 2.9:  Overview of the entrapment of S. pyogenes M1 from fibrin clots. 
After S. pyogenes infection, the host contact system is activated on the bacterial 
surface leading to the induction of the entire clotting cascade and subsequent FXIII-
mediated entrapment of S. pyogenes within the fibrin clot. Immobilized bacteria are not 
able to disseminate within the host and the systemic course of infection is prevented 
(Loof, Deicke and Medina, 2014). 
The protective role of coagulation in innate immunity is highly conserved among 
invertebrates and vertebrates (Loof et al., 2011a). Drosophila transglutaminase (TG) and 
mammalian FXIII, respectively, represent the only clotting factors that have been conserved 
during evolution (Theopold et al., 2002), suggesting an important role of TG/FXIII. A 
protective role of Drososphila TG during innate immunity was demonstrated by Wang and 
colleagues using a Drosophila infection model challenged with different bacterial pathogens 
(Wang et al., 2010). They clearly showed that reduced TG levels resulted in increased 
mortality of infected larvae. TG/FXIII activity from Drosophila hemolymph and human plasma 
accumulated on microbial surface and promoted their sequestration within the clot. The 
activity of FXIII-dependent immobilization of S. pyogenes within fibrin networks as a host 
immune mechanism was also described for vertebrates (Loof et al., 2011b). The pathogen 
entrapment might be promoted by interactions between FXIII and bacterial surface proteins 
such as streptococcal M protein. The authors demonstrated that the entrapment of 
S. pyogenes in vitro was reduced in human FXIII-deficient plasma (Loof et al., 2011b). 
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Additionally, mice lacking FXIII develop more severe signs of inflammation after S. pyogenes 
infection when compared to wild type mice, characterized by massive neutrophil recruitment 
to the infection site and tissue destruction (Loof et al., 2011b). The cross-linking activity of 
FXIII to sequester bacteria within fibrin clots was also reported for E. coli and S. aureus 
(Wang et al., 2010). 
In contrast to this positive contribution of a local induction of coagulation to the innate 
immunity against S. pyogenes infections, activation of systemic coagulation has been 
associated with the development of sepsis and septic shock. Systemic contact activation 
causes widespread fibrin deposition promoting micro- and macro-thrombosis as well as the 
release of BK, a pro-inflammatory and vasoactive peptide and the clinical outcome can be 
dramatically including multi-organ failure, reduced blood pressure, increased vascular 
permeability, fever and pain (Herwald et al., 2003).  
2.3.2.1 Importance of coagulation factor XIII 
The cross-linking of fibrin polymers to generate a stable clot represents the last step of the 
coagulation cascade and is catalyzed by FXIII, also termed fibrin-stabilizing factor. FXIII 
circulates in the blood as a 320-kDa heterotetramer containing two catalytic A and two non-
catalytic carrier B subunits (see Figure 2.10; Hsieh and Nugent, 2008; Yee et al., 1994). The 
catalytic A subunits contain components responsible for the TG activity, activation peptides 
and substrate recognition domains, whereas FXIII B subunits seem to be responsible for the 
protection of the A subunits against proteolysis (Yee et al., 1994). Thrombin activates FXIII 
by proteolysis in the presence of Ca2+ and fibrin. Structural changes lead to the dissociation 
of the B subunits and the catalytic cysteine residue of the A subunit becomes available 
(reviewed by Muszbek et al., 2011). FXIIIa functions as a transglutaminase by catalyzing the 
formation of an “isopeptide” bond between a γ-glutamyl residue of a fibrin molecule and a ε-
lysyl residue of another fibrin molecule (see Figure 2.10). In this way, fibrin polymers are 
stabilized by covalently cross-linking the α- and γ-chains of different fibrin molecules.  
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Figure 2.10: Structure and reaction mechanism of FXIIIa. 
a) X-ray structure of active FXIII (FXIIIa) consisting of two A subunits (blue and 
green) including the four major structural domains: β-sandwich domain, central 
catalytic core domain and two β-barrel domains (PDBe: 1EVU; Yee et al., 1994). 
b) FXIIIa catalyzes the cross-linking reaction of fibrin clots that includes the formation 
of a peptide bond between lysine and glutamine side chains of different fibrin 
monomers (Freeman, 2012). 
The diversity of bleeding disorders observed in patients with FXIII deficiency, a rare 
autosomal recessive syndrome, illustrated the relevance of FXIII in hemostasis (Ivaskevicius 
et al., 2007). Life-long bleeding tendencies, declined wound healing and recurrent 
miscarriages are associated with FXIII deficiency (Ichinose, 2012). Mice deficient in FXIII 
have also been shown to have an impaired wound healing (Lauer et al., 2002). FXIII mainly 
contributes to the prevention of fibrinolysis by fibrin stabilization and binding or incorporation 
of anti-fibrinolytic substrates such as α2-antiplasmin, TAFI and α2-macroglobulin within the 
fibrin clot (Muszbek et al., 2011; Richardson et al., 2013). Additionally, experimental studies 
demonstrated an involvement of FXIII in angiogenesis and wound healing by inducing the 
migration of fibroblasts and macrophages as well as fibroblast proliferation, inhibition of 
apoptosis and cross-linking of ECM proteins and plasma integrins (reviewed by Muszbek et 
al., 2011). FXIII is even involved in the innate immune response against bacterial pathogens 
such as S. pyogenes by mediating the immobilization of these bacteria within fibrin networks 
after infection (see Figure 2.11). This entrapment process is supported by FXIII-mediated 
cross-linking of bacterial surface proteins with the fibrin network (Loof et al., 2011b). 
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Figure 2.11:  Entrapment and immobilization of S. pyogenes within fibrin clots. 
Scanning electron micrographs showing fibrin clots generated from normal plasma (A, 
C and E) and FXIII-deficient plasma (B, D and F) in the absence (A and B) and 
presence of S. pyogenes AP-1 bacteria (C to F). Bacterial entrapment is mediated by 
FXIII resulting in tightly enwoven bacteria, whereas only few bacteria are loose 
associated with the fibrin fibers in the absence of FXIII (Loof et al., 2011b). 
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2.4 Aims of the study 
During the last two decades there is a growing body of evidence that coagulation adopts a 
function within the early innate immune response against invading pathogens. Since it has 
been demonstrated that beside its role in hemostasis and wound healing, coagulation and 
especially FXIII contribute to the host defense against S. pyogenes, the aim of this study was 
the analysis of the molecular mechanisms behind these interactions. FXIII has been shown 
to target bacterial surface structures, such as the streptococcal M1 protein, and mediates the 
bacterial entrapment within fibrin clots. Accordingly, the first aim of this study was: 
1. The analysis of interactions between FXIII and streptococcal surface structures.  
The hypothesis about the general relevance of the FXIII-mediated entrapment as a part of 
the innate immune response against streptococcal infections should be proven. Thus, 
different bacteria belonging to the genus Streptococcus were analyzed for their interactions 
with the fibrin network and FXIII in vitro because the molecular mechanisms behind the 
interactions between streptococcal surface proteins, fibrinogen and FXIII had not been 
discovered yet. Therefore, the second objective of this study was: 
2.  The identification of streptococcal surface structures that are targeted by FXIII.  
The interactions of different streptococcal M and M-like proteins with fibrinogen and FXIII 
should be investigated on the molecular level in vitro. To unravel these mechanisms, 
recombinant streptococcal surface proteins, S. pyogenes wild type and mutant strains as well 
as Lactococcus lactis mutant strains as a heterologous expression system should be used. 
Since FXIII has also been shown to play a role during S. pyogenes infections in vivo, the 
third aim of this study was: 
3. The characterization of the contribution of FXIII in the defense against 
streptococcal infections in vivo. 
To this end, a murine S. pyogenes skin infection model using CBA wild type and FXIII-
deficient mice will be employed. After subcutaneous infection with S. pyogenes the influence 
of FXIII on the development and the outcome of the infection should be investigated.  
Taken together, the experiments performed in the context of this study should gain new 
insights into the role of the coagulation system and especially of FXIII during infections 
caused by streptococci. An improved understanding of these interactions might lead to the 
development of novel antimicrobial and therapeutic approaches against bacterial infections.  
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3 MATERIAL AND METHODS 
3.1 Material 
3.1.1 Chemicals 
Table 3.1:  Chemicals used in this study 
Chemical/solution Company 
2-(N-Morpholino)ethansulfonic acid (MES) Roth 
5x Phusion high fidelity PCR buffer  Thermo Scientific 
6x loading dye (agarose gel electrophoresis)  Fermentas 
10 x FD green Buffer Fermentas 
10 x Taq Polymerase buffer NEB 
10 x T4 Ligase buffer Fermentas 
Acetic acid  Merck 
Acrylamide 30% (Rotiphorese Gel 30)  Roth 
Agar agar Roth 
Agarose Broad range (NEEO Ultra quality)  Roth 
Amersham ECL Prime Western Blotting Detection Reagent GE Healthcare Life Science 
Ammoniumpersulfate (APS)  Serva 
Ampicillin  Applichem 
Bacto™ Tryptone Becton Dickinson 
Bacto™ Yeast Extract  Becton Dickinson 
β Mercaptoethanol  Serva 
Bovine serum albumin (BSA)  Sigma Aldrich 
Bradfod reagent Sigma Aldrich 
Bromophenol blue  Sigma Aldrich 
Calcium chloride (CaCl2)  Merck, Technoclone 
Chloroform  Sigma Aldrich 
Columbia blood agar plates  Becton Dickinson 
Coomassie Brilliant Blue R-250  Sigma Aldrich 
DAPI supplemented mounting media Molecular Probes 
Dapttin® TC Technoclone 
Developer G153 AGFA 
Difco™ M17 broth  Becton Dickinson 
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Dimethylsulfoxid (DMSO)  Sigma Aldrich 
Di-sodiumhydrogenphosphate (Na2HPO4)  Merck 
Desoxyribonucleotides (dNTPs ) Fermentas 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) Roth 
Erythromycin  Sigma Aldrich 
Ethanol  J. T. Baker 
Ethidium bromide  Applichem 
Ethylenediaminetetraacetic acid (EDTA)  Roth 
Fast Fixer AGFA 
Fetal calf serum (FCS) PAA 
Fluoroshield™ with DAPI Sigma 
GeneRuler Ruler™ DNA ladder mix Fermentas 
Glucose  Roth 
Glycerol Roth 
Glycine  Roth 
Hydrochloric acid Roth 
Imidazol Roth 
Isopropyl alcohol  Merck 
Isopropyl β-D-1-thiogalactopyranoside (IPTG)  Applichem 
Kanamycin  Roth 
Lactose  Roth 
Magnesium chloride (MgCl2)  Finnzymes; Roth 
Methanol  J. T. Baker 
PAGE Ruler Prestained Protein Ladder plus Fermentas 
Paraformaldehyde (PFA) solution, 4% in PBS  USB Corporation 
Ponceau S Applichem 
Skim milk powder Sigma Aldrich 
Sodium acetate  Fluka 
Sodium citrate  Fluka 
Sodium chloride (NaCl)  Roth 
Sodium dihydrogene phosphate (NaH2PO4) Roth 
Sodium dodecyl sulphate (SDS)  Sigma Aldrich 
Sodium hydroxide (NaOH)  Merck 
Sucrose  Roth 
Tetramethylethylendiamin (TEMED) Biorad 
Todd Hewitt Broth (THB)  Roth 
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Tris(hydroxymethyl)-aminomethan (TRIS) Sigma Aldrich 
Triton X-100 Sigma 
Trizma base  Sigma Aldrich 
Tween 20  Bio-RAD 
Urea Serva 
3.1.2 Expendable material and instruments 
Table 3.2:  Expendable material and instruments used in this study 
Material/instrument Company 
aPTT measurements 
Balls micro Merlin medical 
Coagulometer MC1 Merlin medical 
Cuvettes Merlin medical 
Ball dispenser Merlin medical 
Centrifugation  
Biofuge 15R Heraeus SEPATECH 
Heraeus Pico17 Thermo Electron Coorperation 
iFuge MO8VT Neuation 
Sorvall® RC6 Plus Thermo Scientific 
Rotor SLA-3000 Thermo Scientific 
Rotor SS-34 Thermo Scientific 
5417c Eppendorf 
Dialysis  
Servpor® dialysis tubing (MWCO 12-14000; 3000)  Serva 
Micro dialysis capsules QuixSep Roth 
Electrophoresis 
Agarose gel electrophoresis chamber Horizon58 Whatman 
Mini Protean III™system Bio-RAD 
Hamilton syringe Whatman 
Power supply Power PA C300 Bio-RAD 
Mini-PROTEAN® TGX™ Precast Gels Bio-RAD 
Electroporation 
Electroporation cuvettes 1mm and 2 mm electrode gap Peqlab 
Gene Pulser™ and pulse controller  Bio-RAD 
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Medical devices 
BD Microlance™ 25G BD Biosciences 
Omnifix®-F Solo (1 mL syringe)  Braun 
Microscopy 
Coverslips (ø 12 mm) Thermo Scientific Thermo Scientific 
Microscope slides 76x 26 mm  Thermo Scientific 
Nikon A1R confocal microscop Nikon Instrument 
Shutter HXP120C Kübler codex 
Zeiss AxioCam MRm Zeiss 
Zeiss Axio Imager A2  Zeiss 
Zeiss Microscope ID03  Zeiss 
Spectrometry/Photometry 
Cuvettes polystyrene 10x 4x 45 mm  Sarstedt 
NanoDrop® 2000c Spectrophotometer Thermo Scientific 
NOVASPEC II Spectrophotometer Amersham Pharmacia Biotech 
SunriseTM microplate absorbance reader Tecan 
Protein purification 
Amicon Ultra Centrifugal Filter devices  Sartorius 
French Press FA-32 Thermo Fischer 
Nickel Nitrilotriacetic acid (Ni NTA) Qiagen 
Single use plastic column Terumo 
Western Blot 
ChemiDoc™ MP System  
Nitrocellulose membranes 0,2 µm Bio-RAD 
Trans-Blot SD Semi-Dry Transfer cell Bio-RAD 
Whatman filter paper  GE Healthcare Life Science 
Other 
Autoclave-steam sterilizer  Biomedis 
Balance vicon Acculab/Sartorius 
Cell Star® 15 ml tubes Greiner bio-one tubes Greiner bio-one 
Cell Star® 50 ml tubes Greiner bio-one Greiner bio-one 
Cryo tube™ vial Nunc™ Nunc™ 
Dynabeads® MyOne™ Carboxylic Acid Invitrogen 
ErgoOne Pipettes (5000, 1000, 200, 20 µl, Multipipette) Starlab 
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FastPrep®-24 Instrument MP 
Immuno 96 MicroWell™ Solid Plates Thermo Fisher Scientific 
Micro tube 1.5 ml  Sarstedt 
MS1 Minishaker IKA 
PCR tubes 0.2 ml  Starlab 
Petri dish  Greiner bio-one 
pH-meter 766  Calimatic Knick 
POLYTRON PT 2100 homogenizer  KINEMATICA AG 
Roller mixer SRT6  Stuart 
Servpor ® dialysis tubing (different MWCO)  Serva 
Thermomixer 5436 Eppendorf 
Tpersonal Thermocycler Biometra 
Waterbath GFW 
Zirconia/silica beads Roth 
3.1.3 Proteins and enzymes 
Table 3.3: Proteins and enzymes used in this study 
Protein/Enzyme Company 
BamHI FD Fermentas 
Bovine serum albumin (BSA) Bio-RAD 
Coagulation factor XIII (FXIII) Enzyme Research Laboratories 
EcoRI FD Fermentas 
EcoRV FD Fermentas 
FastAP Fermentas 
Fibrogammin®P FXIII concentrate CSL Behring 
Fibrinogen (from human plasma) Sigma 
Fibrinogen-binding protein of GGS (FOG) kindly provided by Dr. G. Gulotta and PD 
Dr. D.P. Nitsche-Schmitz; HZI 
Hemoclot thrombin reagent Hyphen BioMed 
Lysozyme Sigma 
Mouse interleukin 6 (mIL6) BioLegend 
Mouse interleukin 10 (mIL10) BioLegend 
Phusion DNA polymerase Finzymes/Thermo Scientific 
Proteinase Inhibitor Cocktail Tablets, 
cOmplete MINI, EDTA-free 
Roche Diagnostics 
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Proteinase K Fluka 
PstI FD Fermentas 
Rnase (DNase free) Applichem 
SalI FD Fermentas 
Streptococcal M1A3 construct Master thesis Caroline Wesener 
Streptococcal M3A1 construct Master thesis Caroline Wesener 
Streptococcal M1-2 protein Kindly provided by Dr. G. Gulotta and PD 
Dr. D.P. Nitsche-Schmitz, HZI 
Streptococcal M3 protein Kindly provided by Dr. G. Gulotta and PD 
Dr. D.P. Nitsche-Schmitz, HZI 
Streptococcal M55 protein Kindly provided by Dr. G. Gulotta and PD 
Dr. D.P. Nitsche-Schmitz, HZI 
T4 ligase Fermentas 
3.1.4 Antibodies and plasma 
Table 3.4.: Antibodies and plasma used in this study 
Antibody/serum  Dilution Application Source/company 
Alexa 488 conjugated 
donkey-anti-rabbit IgG 
 fluorescence microscopy Molecular Probes, 
Eugene, OR, USA 
Alexa 647 conjugated 
donkey-anti-goat IgG 
 fluorescence microscopy Molecular Probes, 
Eugene, OR, USA 
Fetal calf serum (FCS)  Cultivation of pneumococci; 
ELISA; Immunofluores-
cence microscopy  
PAA 
FXIII-deficient plasma  clotting assays George King Bio-
Med Inc. 
goat anti-rabbit antibody 
Alexa 488 green conjugated 
1:200 fluorescence microscopy Abcam 
goat anti-rabbit antibody 
HRP conjugated 
1:3000 western blot Dako 
goat polyclonal anti-
Streptococcus pyogenes 
group A 
 fluorescence microscopy Abcam, 
Cambridge, UK 
normal plasma  clotting assays Healthy 
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volunteers 
Plasminogen-deficient 
plasma 
 clotting assays Affinity Biological 
Inc. 
rabbit anti-fibrinogen 
antibody 
1:10 000 western blot Dako 
rabbit polyclonal anti-factor 
XIIIa 
 fluorescence microscopy Bioss Inc., 
Woburn, MA, USA 
rabbit anti-streptoccocal M1 
protein antibody 
1:3000 fluorescence microscopy Kindly provided by 
Dr. S. Talay (HZI, 
Braunschweig) 
3.1.5 Kits 
Table 3.5: Kits used in this study 
Kit Company 
Dneasy Blood and Tissue Kit Qiagen 
Midi Präp Qiagen 
QIAprep® Spin Miniprep Kit Qiagen 
mouse IL-6 ELISA Kit BioLegend 
PCR and Gel Clean-Up Kit Machery-Nagel 
Phire Animal Tissue Direct PCR Kit Thermo Scientific 
TOPO ® TA Cloning Kit Invitrogen 
3.1.6 Antibiotics 
Table 3.6: Antibiotics used in this study 
Name Application Final concentration 
Ampicillin Cultivation of E. coli 100 µg/ml 
Erythromycin Cultivation of S. pyogenes und L. lactis 5 µg/ml 
Kanamycin Cultivation of E. coli 50 µg/ml 
Spectinomycin Cultivation of S. dysgalactiae ssp. equisimilis 80 µg/ml 
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3.1.7 Plasmid vectors 
Table 3.7: Plasmid vectors used in this study 
Vector  Vector size Selection conditions Reference/source 
pCR2.1-TOPO 3900 bp 100 µg/ml Ampicillin 
50 µg/ml Kanamycin 
Invitrogen 
pDCerm 4690 bp  500 μg/ml erythromycin  Kindly provided by Prof. 
V. Nizet, University of 
California, San Diego  
pOri23  E. coli: 400 µg/ml Erythromycin 
L. lactis: 5 µg/ml Erythromycin 
 
pQE30 3460 bp 100 µg/ml Ampicillin Qiagen 
3.1.8 Oligonucleotides 
Table 3.8: Oligonucleotides used in this study 
Name  Sequence 5’-3’  Tm 
[°C] 
Ta 
[°C] 
Annotation/ 
reference 
Primer for cloning of the B repeat region of streptococcal M1 protein (AP-1) 
B-for new2 AGTTGGGATAGAGGATCCCTTGA
AAAAGAG 
65,4 55 This study 
B-R2-new2 CCCGTCGACTTATTCTAACTCTTT
TTCTAAGACGTTAGC 
69,5 55 This study 
Primer for amplification of genes inserted into pCR2.1-Topo vector (TOPO cloning) 
M13 for GTAAAACGACGGCCAG 54 60 Invitrogen 
M13 rev CAGGAAACAGCTATGAC 20 60 Invitrogen 
Primer for amplification of genes inserted into pQE30 
pQE 5' 
Promoter 
SeqP (Nr. 94) 
CCCGAAAAGTGCCACCTG 58 60 Primer collection, 
former MMIK Dept., 
HZI 
pQE 3' SeqP 
(Nr. 96) 
GTTCTGAGGTCATTACTGG 56 60 Primer collection, 
former MMIK Dep. 
HZI 
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Primer for classification of S. pyogenes strains (amplification of the A region of 
streptococcal M1 protein) 
all emmA TATTCGCTTAGAAAATTAA 46 
 
52 Primer collection, 
former MMIK Dep. 
HZI 
all emmB GCAAGTTCTTCAGCTTGTTT 56 52 Primer collection, 
former MMIK Dep. 
HZI 
Amplification of gene sequences for truncated emm1 gene without A region 
emm_f_avrII TGTACACCTAGGGATAGACAAAG
ACTTGAAAAA 
64,5 55 This study 
emm_r_avrII TCCCTAGGATTACCATCACCGTT 60,6 55 This study 
3.1.9 Bacterial strains 
3.1.9.1 Streptococcus pyogenes strains (Group A Streptococci, GAS) 
Table 3.9: S. pyogenes strains used in this study 
Strain  Serotype Phenotype Origin/condition Reference/source 
S. pyogenes 
5448  (A749) 
M1T1 wild type  Chatellier et al., 2000 
S. pyogenes 
5448 Δ emm1 
M1T1 ΔM1  Lauth et al., 2009 
S. pyogenes 
AP-1 (A529) 
M1 wild type  Åkesson et al, 1990 
S. pyogenes 
MC25 
M1 ΔM1 150 µg/ml 
Kanamycin 
Mattias Collin, Lund 
University, Sweden 
S. pyogenes 
A600 
M3 wild type  B.J. Vlaminckx ; 
University Medical Center 
Utrecht, The Netherlands 
S. pyogenes 
A666 
M6 wild type  B. J.Vlaminckx ; 
University Medical Center 
Utrecht, The Netherlands 
S. pyogenes 
A304 
M49 wild type clinical  skin 
isolate  
Andreas Podbielski 
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S. pyogenes 
AP-53 (A751) 
 wild type  Marc Walker, University of 
Queensland, Australia 
S. pyogenes 
A856 
M3.23 wild type  Strain collection former 
MMIK Dep. HZI 
3.1.9.2 Group G Streptococci 
Table 3.10:  GGS strains used in this study 
Strain  Serotype Phenotype Origin/condition Reference/source 
S. dysgalactiae 
ssp. equisimilis 
G45 
StG11 Wild type  Strain collection former 
MMIK Dep. HZI 
S. dysgalactiae 
ssp. equisimilis 
G89 
StG11 Δ FOG 
(pJRS233 -
Fog-Spc) 
80 µg/ml 
Spectinomycin; 
1 µg/ml Erythomycin 
Strain collection former 
MMIK Dep. HZI 
3.1.9.3 Other streptococci strains 
Table 3.11:  Other streptococci strains used in this study 
Strain Name Serotyp Origín/Reference 
Streptococcus pneumoniae 
D39 (P35) 
7466 Typ 2 NCTC, laboratory strain 
Streptococcus oralis  
SV 215 
  Strain collection former MMIK Dep. HZI 
3.1.9.4 Escherichia coli strains 
Table 3.12: E. coli strains used in this study 
Strain Plasmid Culture conditions Reference/Source 
E. coli DH5ɑ   Strain collection former 
MMIK Dep. HZI 
E. coli M15 pREP4 25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
Qiagen (1994) 
E. coli M15 + A1M3 
construct  
pREP4  
pQE30-A1M3 
25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
Master thesis Caroline 
Wesener (2015) 
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E. coli M15 + A3M1 
construct 
pREP4 
pQE30-A3M1 
25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
Master thesis Caroline 
Wesener (2015) 
E. coli M15 + A region 
of M1 protein (AP-1) 
pREP4 
pQE30-A 
region 
25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
Kindly provided by Dr. 
Giuseppe Gulotta and 
PD Dr. D.P. Nitsche-
Schmitz, HZI 
E. coli M15 + ABs 
construct of M1 protein 
(AP-1) 
pREP4 
pQE30-ABs 
25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
Kindly provided by Dr. 
Giuseppe Gulotta and 
PD Dr. D.P. Nitsche-
Schmitz, HZI 
E. coli M15 + B repeats 
of M1 protein (AP-1) 
pREP4 
pQE30-B 
repeats 
25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
This study 
E. coli M15 + sCD 
construct of M1 protein 
(AP-1) 
pREP4 
pQE30-sCD 
construct 
25 µg/ml Kanamycin 
100 µg/ml Ampicillin 
Kindly provided by Dr. 
Giuseppe Gulotta and 
PD Dr. D.P. Nitsche-
Schmitz, HZI 
E. coli TOP10   Invitrogen (1994) 
3.1.9.5 Lactococcus lactis strains 
Table 3.13: L. lactis strains used in this study 
Strain  Plasmid Insert/characteristics Culture 
conditions 
Reference 
L. lactis  
 
 
pLM1 
(pVE5508 with 
emm1) 
Replacement of emm6 
within  pLM1 
5 μg/ml 
erythromycin; 
30°C 
 
Cue et al., 
2001 
L. lactis  pP59 Deletion of emm6 
from pVE5508  
 
5 μg/ml 
erythromycin; 
30°C 
Cue et al., 
2001 
L. lactis A1M3 pOri23-A1M3 Insertion of emm3 
gene with A region of 
emm1 gene (A1M3 
5 μg/ml 
erythromycin; 
30°C 
Master thesis 
Caroline 
Wesener 
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construct)  (2015) 
L. lactis A3M1 pOri23-A3M1 Insertion of emm1 
gene with A region of 
emm3 gene (A3M1 
construct) 
5 μg/ml 
erythromycin; 
30°C 
 
Master thesis 
Caroline 
Wesener 
(2015) 
L. lactis M3 pOri23-M3 Insertion of emm3 
gene (S. pyogenes 
A856) 
5 μg/ml 
erythromycin; 
30°C 
Master thesis 
Caroline 
Wesener  
L. lactis M1∆A pOri23-M1∆A Insertion of emm1 
gene without A region 
5 μg/ml erythro-
mycin; 30°C 
This study 
3.2 Microbiological methods 
3.2.1 Cultivation of bacterial strains 
S. pyogenes strains were cultured in THY medium and supplemented with antibiotics if it was 
necessary for the mutant strains. Bacterial cultures were prepared in sterile Falcon tubes and 
cultured overnight at 37°C and 5% CO2 without agitation. Streptococcus viridans strains were 
cultured under similar conditions than S. pyogenes strains. 
S. pneumoniae strains were grown in THY medium containing 1% yeast extract at 37°C and 
5% CO2, overnight without agitation. 
E. coli strains were cultured in LB medium containing the appropriate antibiotics overnight at 
37°C with agitation (120 rpm). 
For the L. lactis cultivation, M17 medium supplemented with 0,5% glucose and the appro-
priate antibiotic was used. Lactococci were cultured overnight at 30°C without agitation. 
For long term storage of bacteria, glycerol stocks were prepared. To this purpose 750 µl 
bacterial overnight culture were mixed with 250 µl sterile glycerol and kept at -80°C. 
THY medium    30 g/l Todd Hewitt Broth  
5 g/l Bacto™ Yeast Extract *  
ad 1 l dH2O 
*for S. pneumoniae 10 g/l Bacto™ Yeast Extract was used 
Luria Bertani (LB) medium  10 g/l Bacto™ Tryptone  
5 g/l Bacto™ Yeast Extract  
10 g/l NaCl  
ad 1 l dH2O 
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M17 medium    37.25 g/l Difco™ M17 broth powder  
950 ml dH2O  
50 ml 10% Lactose (added after sterilization and cooling 
to 50°C) 
For preparation of the corresponding agar plates, 15 g/l of agar agar was added to the 
medium before autoclaving. 
3.2.2 Monitoring of bacterial growth and adjusting of bacterial suspensions 
Bacterial growth was monitored by measuring the optical density at a wavelength of 600 nm 
(OD600) using a spectrophotometer. 
To adjust comparable bacterial amounts, especially for experiments with streptococci, the 
transmission at a wavelength of 600 nm (T600) was measured. Bacterial concentrations were 
adjusted taking into account that a T600 of 10% corresponds to a bacterial concentration of 
approximately 5 ×108 cfu/ml.  
3.2.3 Preparation and transformation of competent bacteria 
Transformation was used to insert foreign DNA or artificial DNA constructs into the desired 
bacterial strains. This method uses the property of certain bacteria, like E. coli, to achieve 
foreign DNA by horizontal gene transfer. 
3.2.3.1 Preparation of chemical competent E. coli cells 
Initially, 100 ml LB medium supplemented with appropriate antibiotics were inoculated with 
an overnight culture of the relevant E. coli strain in a ratio 1:100. Bacteria were grown up to 
OD600 between 0.4 and 0.45 at 37°C and 120 rpm. After 10 min incubation on ice, cultures 
were centrifuged for 10 min at 5 000 rpm and 4°C. The supernatant was discarded and the 
pellet was resuspended in 50 ml ice cold MgCl2. After centrifugation for 10 min at 5 000 rpm 
and 4°C, the pellet was resuspended in 50 ml ice cold CaCl2. After another centrifugation 
step (see above), the bacterial pellet was resuspended in 4 ml ice cold CaCl2/Glycerol 
solution and incubated on ice for 20 min. Cell suspension was aliquoted to 200 µl, snap 
frozen in liquid nitrogen and stored at -80°C until use. 
MgCl2     100 mM 
CaCl2     50 mM 
CaCl2/Glycerol   50 mM CaCl2  
     12,5 % (V/V) Glycerol 
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3.2.3.2 Transformation of chemically competent E. coli cells 
Briefly, cells were thawed on ice and 2 µl of plasmid DNA / 5 µl ligation reactions were 
added. The mixture was incubated on ice for 15 to 30 min and subjected to a heat shock for 
30 s at 42°C. Bacteria were resuspended in 950 µl of LB medium without antibiotics and 
further incubated for at least 45 min at 37°C and 450 rpm. At the end, 50 to 100 µl of 
bacterial suspension were plated on selective LB agar plates containing the appropriate 
antibiotic and incubated overnight at 37°C.  
After transformation of ligation products, the selected bacterial colonies, probably carrying 
the desired insert, were checked by colony PCR (see section 3.3.4.2) and DNA sequence 
analysis (see 3.3.10). 
3.2.3.3 Preparation of electro competent E. coli cells 
E. coli was grown overnight in LB medium and a subculture was prepared at a ratio of 1:100 
in 500 ml LB medium containing the appropriate antibiotic. Bacteria were then grown at 37°C 
and 120 rpm to a maximum OD600 of 0.6 and incubated on ice for 15 to 30 min. After 
centrifugation for 10 min at 5 000 rpm and 4°C, cells were washed with 250 ml ice-cold water 
followed by another washing step with 250 ml ice-cold water containing 10% glycerol. Finally, 
the bacterial pellet was resuspended in 1 ml of 10% (V/V) glycerol and incubated on ice for 
5 min. Bacterial suspensions were aliquoted, snap frozen in liquid nitrogen and stored at -
80°C until use. 
3.2.3.4 Transformation of electrocompetent E. coli cells 
Bacterial suspensions were mixed with 1 µl plasmid DNA / 2 – 5 µl ligation products and 
transferred to precooled electroporation cuvettes. Electrocompetent cells were transformed 
by electroporation with 2.5 kV, 25 µF and 200 Ω followed by rapid addition of 250 µl LB 
medium. Cells were incubated at 37°C and 120 rpm for at least 45 min, followed by plating 
on selective LB agar plates containing the appropriate antibiotic. Bacterial colonies were 
checked for inserted DNA as described above. 
3.2.3.5 Preparation of competent L. lactis cells 
To prepare competent L. lactis cells, 45 ml of GM17 medium containing 1% glycine were 
inoculated with 5 ml of an overnight culture. Cells were grown to an OD600 of 0.3, spun down 
for 10 min at 4 000 rpm and 4°C and pelleted bacterial cells were washed three times with 
20 ml of a sucrose/glycerol solution. Between each washing step, cells were centrifuged for 
10 min at 4 000 rpm and 4°C. Finally, cells were resuspended in 250 µl sucrose/glycerol 
solution, aliquoted and either directly used for transformation or snap frozen in liquid nitrogen 
and stored at -80°C until use. 
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GM17  medium   18.63 g M17 browth 
475 ml dH2O 
25 ml sterile 10% (w/V) glucose (added after sterilization 
and cooling to 50°C) 
GM17 + 1 % glycine   18.63 g M17 browth 
5 g glycine  
475 ml dH2O 
25 ml sterile 10% (w/V) glucose (added after sterilization 
and cooling to 50°C) 
For preparing the corresponding agar plates, 15 g/l of agar agar was added to the medium 
before autoclaving. 
Sucrose/glycerol solution  0.5 M Sucrose 
     10 % (V/V) glycerol      
3.2.3.6 Transformation of competent L. lactis cells 
A volume of 50 µl competent L. lactis bacteria was carefully mixed with 0.5 – 1 µg of DNA on 
ice. Bacteria were transformed by electroporation using 2000 V. Immediately after 
electroporation, 750 µl recovery buffer were added and the mixture was incubated at 30°C 
for at least 2 h. Finally, cells were plated on GM17 plates containing two different 
concentrations of the appropriate antibiotic (in this study 3 and 5 µg/ml erythromycin) and 
incubated at 30°C for a period of 2 to 3 days. 
Recovery Buffer   GM17 
0.5 M Sucrose 
20 mM MgCl2  
2 mM CaCl2 
3.2.4 Immobilization of S. pyogenes within the fibrin network 
S. pyogenes was cultured as described above (see 3.2.1). For immobilization experiments 
5 × 105 cfu bacteria in a volume of 100 µl sodium citrate buffer were mixed with 100 µl of 
normal or FXIII-deficient human plasma. Clotting was induced by the addition of 50 µl 
Hemoclot Thrombin reagent. Clots were then covered with 1 ml of 1% normal or FXIII-
deficient human plasma and 50 µl of the supernatant were immediately plated onto blood 
agar in 10 fold serial dilutions. The number of bacteria was determined by counting colonies 
after 18 h of incubation at 37°C and 5% CO2.  
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Sodium citrate    12,9 mM 
3.3 Molecular biology methods 
3.3.1 Isolation of chromosomal DNA from S. pyogenes 
To isolate chromosomal DNA from S. pyogenes, 10 – 15 ml of an overnight culture were 
centrifuged for 7 min at 3 700 x g. The resulting bacterial cell pellet was resuspended in 
180 µl TE buffer and 20 µl of DNase-free RNase (c0 = 10 µg/ml) were added. The solution 
was transferred to ca. 250 µl sterile zirconia beads and cells were lysed by using a cell 
homogenizer for 30 s with a velocity of 4 m/s. After addition of 200 µl of buffer AL, the beads 
were spun down for 30 s. The lysate was subsequently transferred into a new reagent tube 
and the zirconia beads were discarded. To remove the remaining proteins, 25 µl of 
proteinase K were added, tubes were gently inverted and incubated at 56°C for 30 min. To 
precipitate the DNA, 200 µl of ethanol (96 – 100%, p.a.) were added and the complete 
mixture was applied to a DNeasy Mini spin column. After centrifugation for 1 min at 8 000 
rpm, the flow-through was discarded and the retained DNA was washed by adding 500 µl of 
buffer AW1 and centrifuging for 1 min at 14 000 rpm. The flow-through was discarded and 
the membrane was dried by centrifuging for 1 min at 14 000 rpm. Finally, DNA was eluted by 
the addition of 200 µl buffer AE followed by a 5 min incubation step and centrifugation for 1 
min at 8 000 rpm. The quality of DNA was verified by agarose gel electrophoresis (see 
3.3.3). 
Buffer AL, AW1, AE and DNeasy Mini spin columns were provided with the DNeasy Blood 
& Tissue Kit by Qiagen. 
TE buffer    10 mM TRIS/HCl 
     1 mM EDTA    pH8.0 
3.3.2 Isolation of plasmid DNA  
Plasmid DNA from E. coli cells was prepared by using the QIAprep® Spin Miniprep kit 
according to the manufacturer´s instructions. Isolated DNA was analyzed by agarose gel 
electrophoresis (see section 3.3.3) and stored at -20°C until use. 
3.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used ror quantitative and qualitative analysis of DNA 
molecules after plasmid and chromosomal DNA isolation. For preparation of agarose gels, 
the appropriate amount of agarose was solved in 1 x TAE by boiling. DNA samples were 
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mixed with 6 x DNA loading dye and loaded on the gel. GeneRuler™ DNA ladder mix was 
used as a molecular weight standard and 1 x TAE was used as running buffer. 
Electrophoresis was performed for approximately 40 – 60 min at 100 V. Agarose gels were 
incubated in an ethidium bromide solution (1 μg/ml in H2O) for 10 min and the DNA was 
visualized by using an UV-transilluminator or a Bio-RAD GelDoc station.  
TAE (Tris Acetate EDTA)   2 M Tris/HCl,    pH 8.5 
1 M Acetic acid 
100 mM EDTA 
3.3.4 Polymerase chain reaction (PCR) 
3.3.4.1 Standard PCR  
The standard PCR protocol was used to amplify defined DNA fragments out of a longer 
template DNA (chromosomal DNA, plasmid DNA) and to introduce specific restriction sites 
into defined genes to enable whose cloning into plasmid vectors. 
Standard PCR Protocol 
Table 3.16: Standard PCR protocol 
Reagent Stock 
concentration 
Final concentration/ 
amount 
Template DNA  100 – 500 ng 
Phusion PCR buffer with MgCl2 5 x 1 x 
dNTPs 2 mM 200 µM 
Primer forward  10 pmol/μl 300 nM 
Primer reverse 10 pmol/μl 300 nM 
Phusion high fidelity DNA polymerase  2 U/μl 0,04 U/µl 
MQ H2O  ad 50 µl 
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Standard PCR program 
Table 3.17: Standard PCR program 
Reaction step Temperature Time 
Initial denaturation 98°C 1 min 
Denaturation  98°C 30 s 
Annealing Ta 30 s 
Elongation 72°C te 
Final elongation 72°C 5 min 
 4°C ∞ 
Ta: Annealing temperature, primer specific 
te: Elongation time, dependent on the length of the desired PCR product and the processivity of the 
polymerase which is used (Phusion polymerase ~1 kb/30 sec, Taq polymerase ~1 kb/1 min) 
3.3.4.2 Colony PCR 
Colony PCR was the method of choice to check bacterial clones for the desired DNA insert 
after ligation, transformation and antibiotic selection. For this purpose a single bacterial 
colony was resuspended in 50 µl sterile MQ water and the cells were lysed by boiling for 
10 min at 95°C. The released DNA was used as a template for PCR which was performed 
according the protocol described below (Table 3.18). 
Table 3.18: Colony PCR protocol 
Reagent Stock 
concentration 
Final concentration/ 
amount 
Template DNA  2 µl 
Taq PCR buffer  10 x 1 x 
MgCl2 25 mM 2.5 mM 
dNTPs 2 mM 200 µM 
Primer forward  10 pmol/μl 300 nM 
Primer reverse 10 pmol/μl 300 nM 
Taq DNA polymerase  2 U/μl 0.05 U/µl 
MQ H2O  ad 20 µl 
 
 
30 x 
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Table 3.19: Colony PCR program 
Reaction step Temperature Time 
Initial denaturation 95°C 1 min 
Denaturation  94°C 15 s 
Annealing Ta 30 s 
Elongation 72°C te 
Final elongation 72°C 5 min 
 4°C ∞ 
3.3.5 Determination of DNA concentration 
The A260 was measured using the Nanodrop spectrophotometer and DNA content was 
calculated by stating that an A260 of 1,0 at 260 nm corresponds to a concentration of 50 µg/ml 
of double-stranded DNA.  
3.3.6 Specific restriction of DNA 
Restriction reactions were performed according to the protocol below (Table 3.20) for 3 h or 
overnight at 37°C. In some cases, it was necessary to inactivate the restriction enzymes after 
the reaction following the manufacturer´s instructions. 
Table 3.20: Specific restriction protocol 
Reagent Stock 
concentration 
Final concentration/ 
amount 
DNA (Plasmid DNA or PCR product) various 1 µg 
Restriction buffer 10 x 1 x 
Restriction endonuclease I  1 µl/1 µg DNA 
Restriction endonuclease II  
(if necessary) 
 1 µl/1 µg DNA 
MQ H2O  ad 50 µl 
3.3.7 Dephosphorylation of DNA after specific restriction 
Alkaline phosphatase (AP) dephosphorylates the 5´ terminus of vector DNA and thus avoids 
re-ligation of linearized plasmid vector DNA after specific restriction. 1 U of AP was added 
after specific restriction and samples were incubated at 37°C for 1 h. 
30 x 
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3.3.8 Ligation 
Ligation is the method of choice to covalently link DNA molecules and is mainly used to 
insert specific DNA fragments into distinct plasmid vectors. This reaction is catalyzed by T4 
DNA ligase which connects free 3´ hydroxy groups with free 5´ phosphate groups by 
formation of a phosphodiester bond. For ligation insert DNA and vector DNA, after specific 
restriction, were used in a ratio of 5:1 or 3:1 (see Equation 3.1). Reactions were prepared 
according to the protocol below (Table 3.21) and incubated overnight at 4 or 16°C. Ligation 
products were either directly used to transform competent bacteria or stored at – 20°C. 
Table 3.21: Ligation protocol 
Reagent Stock concentration Final concentration/amount 
T4 Ligase buffer 10 x 1 x 
Vector DNA Various 25 ng 
Insert DNA Various x 
T4 DNA Ligase 5 U/µl 2.5 U 
MQ H2O  ad 20 µl 
The amount of insert DNA which is used for ligation into a distinct plasmid vector was 
calculated using the following equation (Mülhardt, 2006):  
Equation 3.1:  Ligation ratios 
Amount of insert DNA [ng] =  ோ ௫ ௔௠௢௨௡௧ ௢௙ ௩௘௖௧௢௥ ஽ே஺ 
[௡௚]௫ ௦௜௭௘ ௢௙ ௜௡௦௘௥௧ ஽ே஺ [௕௣]
௦௜௭௘ ௢௙ ௩௘௖௧௢௥ ஽ே஺ [௕௣]
 
R: dependent on the ratio between insert and vector DNA (5:1 or 3:1) 
3.3.9 Purification of PCR products and DNA from agarose gels 
PCR products and DNA bands were cut off from agarose gels and purified using the PCR 
and Gel Clean-Up Kit by Machery-Nagel according to the manufacturer´s protocol. 
3.3.10 DNA sequencing 
The DNA sequence of the generated DNA constructs was checked by DNA sequencing 
performed by the HZI sequencing service (Group GMAK) using the chain-terminating method 
(Sanger et al., 1977). DNA sequence data was evaluated using Bioedit software. 
3.3.11 Desalting of DNA solutions by micro dialysis 
A small petri dish was filled up with sterile MQ water and a membrane filter (pore size: 
0.025 µm) was placed on the water surface. The DNA solution was then carefully pipetted 
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onto the membrane filter and incubated for 30 min at RT. The DNA solution was removed 
from the filter and used to transform electro competent E. coli cells. 
3.3.12 TOPO cloning method 
The TOPO cloning strategy comprises three successive steps. In a first reaction adenosine 
(A) residues were added to the desired PCR product. For that purpose, the following reaction 
was prepared (Table 3.22) and incubated at 72°C for 10 min. 
Table 3.22: TOPO cloning protocol – addition of A residues 
Reagent Volume 
PCR product 10 ng / ca. 2 µl 
10 x Taq polymerase reaction buffer 0.4 µl 
dNTPs (or dATPs) 0.1 µl 
Taq DNA polymerase 0.25 µl 
ddH2O 1.25 µl 
 
Afterwards the TOPO cloning reaction was performed following to the protocol below (Table 
3.23). The reaction was incubated at RT for 1 h. Mixtures were then stored on ice until 
transformation of chemical competent E. coli TOP10 cells (see section 3.2.3.2). 
Table 3.23: TOPO cloning protocol – TOPO cloning reaction 
Reagent Volume 
PCR product with A overhangs 2 µl 
Salt solution 1 µl 
TOPO vector 0.5 µl 
ddH2O ad 6 µl 
3.4 Protein chemistry methods 
3.4.1 Recombinant protein production in E. coli 
The QIAexpress system was used for recombinant protein production. This heterologous 
expression system offers high-level production of target proteins containing a hexa-histidin 
tag (6x His tag) in E. coli. To this purpose, the desired DNA constructs were inserted into the 
multiple cloning site (MCS) of the appropriate pQE30 plasmid vector. To effectively regulate 
the extremely high transcription rate, E. coli M15 cells were used as host strains for 
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recombinant gene expression. These cells contain, beside the described expression plasmid 
(pQE30), the plasmid pREP4 which constitutively expresses the lac repressor protein for 
transcription repression. Therefore, gene expression can be induced rapidly and tightly 
controlled by the addition of isopropyl-β-D-thiogalactoside (IPTG) that binds to the repressor, 
leading to the release from the promotor to enable the binding of RNA polymerase and 
transcription. 
 
Figure 3.1: Vector map of pQE30.  
The pQE plasmid vector contains different restrictions sites (BgaI, XhoI, EcoRI, XbaI), 
a ribosomal binding site (RBSII), an antibiotic selection marker (gene for β-lactamase 
for ampicillin resistence), an origin of replication (ori), a promotor/operator region and 
the DNA sequence for a histidine tag (6x His tag) (adapted from “The 
QIAexpressionist” manual, Qiagen, 06/2003). 
3.4.1.1 Test of recombinant gene expression 
A volume of 20 ml of LB medium supplemented with ampicillin and kanamycin were 
inoculated from an overnight culture of E. coli M15 in a 1:100 ratio and incubated at 37°C 
and 120 rpm. IPTG was added (final concentration 1 mM) when the bacterial culture reached 
an OD600 of 0.5 – 0.8 to induce gene expression. Optimal gene expression was determined 
by growing the bacteria for 4 to 6 h at different temperatures (e. g. 25°C, 30°C and 37°C). A 
250 µl sample was taken from each culture hourly and immediately centrifuged for 5 min at 
10 000 rpm. Cells were lysed by resuspension in urea buffer and by addition of 5 x SDS 
sample buffer. Gene expression was analyzed by SDS PAGE. 
Urea buffer    8 M Urea  
100 mM Na2HPO4  
10 mM TRIS/HCl 
3.4.1.2 Recombinant gene expression  
For the expression of desired DNA constructs, a specific volume of LB medium 
supplemented with ampicillin and kanamycin as well as 0.05 % (V/V) glucose was inoculated 
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with a E. coli M15 overnight culture in a 1:100 ratio. Cells were grown to an OD600 of 1.0 – 
1.2 at 37°C with agitation and gene expression was induced by the addition of IPTG (final 
concentration 1 mM) under the determined optimal conditions. Cells were harvested by 
centrifugation for 20 min at 4 500 rpm and 4°C (rotor SA-3000), the wet weight of the 
bacterial cells was determined and the bacterial cell pellet was stored at -20°C until use.  
3.4.2 Purification of recombinant proteins 
In this study proteins of interest (POI) were purified by immobilized metal chelate affinity 
chromatography (IMAC), a common method to purify his-tagged POIs with high 
homogeneity. For purification of soluble proteins, bacterial pellets were resuspended after 
recombinant expression in 5 ml of purification buffer I per gramm of bacterial wet weight and 
cells were disrupted by using a high-pressure cell homogenizer (french press). A protease 
inhibitor mix was added to prevent degradation of proteins after cell lysis. Bacterial cells were 
disrupted by pressing three times. To separate cell debris from soluble proteins, cell lysates 
were centrifuged for 30 min a 12 000 rpm and 4°C (rotor: SS-34). Ni-NTA agarose was 
resuspendend and 6 ml were pipetted into a fresh single use plastic column. The Ni-NTA 
matrix was equilibrated with 5 – 10 column volumes (CV) purification buffer I. The 
supernatant containing the soluble protein fraction including the POI was loaded onto the Ni-
NTA matrix and the protein mixture was allowed to slowly pass through the purification matrix 
and the 6 x His-tagged POI to bind to the matrix. This loading step was repeated twice. The 
flow-through was collected and stored at 4°C. E. coli proteins which bound unspecificly to the 
Ni-NTA matrix by natural histidine residues were removed by washing four times with 5 ml 
purification buffer II which contained low imidazole concentrations. Washing fractions were 
collected and stored at 4°C. Elution of the POI from the Ni-NTA matrix was performed using 
high imidazole concentrations. To this end, 3 ml of purification buffer III were pipetted onto 
the Ni-NTA matrix, incubated for 5 min and allowed to pass through the Ni-NTA matrix. The 
flow-through of this step (eluate) contains the POI. The elution step was repeated twice. 
Elution fractions were collected and stored at 4°C. The success of protein purification was 
determined by SDS-PAGE analysis. 
Purification Buffer I   50 mM NaH2PO4 
      300 mM NaCl   pH 8.0 
Purification Buffer II    50 mM NaH2PO4 
      300 mM NaCl 
      20 mM Imidazol  pH 8.0 
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Purification Buffer III    50 mM NaH2PO4 
      300 mM NaCl 
      250 mM Imidazol  pH 8.0 
3.4.3 SDS polyacrylamide gel electrophoresis 
Complex prortein mixtures and protein sizes were analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli 
(Laemmli, 1970). Protein samples were prepared by boiling at 95°C for 5 min in SDS sample 
buffer and then loaded on the SDS gel. For electrophoresis, a constant current of 20 mA/gel 
was set up for protein migration through the stacking gel and 30 mA/gel were used after 
samples had reached the resolving gel. After electrophoresis gels were stained with 
Coomassie solution and proteins bands were visualized after destaining. 
5 x sample buffer (reducing)   100 mM TRIS/HCl    pH 8 
16% (v/v) Glycerol 
4.8% (w/v) SDS 
0.1% (w/v) Bromine phenol blue 
2% (v/v) β mercapto ethanol 
Resolving gel buffer   1.5 M TRIS/HCl    pH 8.8 
Stacking gel buffer    0.5 M TRIS/HCl   pH 6.8  
SDS Running buffer    250 mM TRIS/HCl 
1.9 M Glycine 
1% (w/V) SDS  
ad 1 l MQ H2O 
Coomassie Staining solution  40% (V/V) Methanol  
10% (V/V) Acetic acid  
1 g/l Coomassie Brilliant blue R250  
ad 1l MQ H2O 
Destaining solution    40% (V/V) Methanol  
10% (V/V) Acetic acid 
ad 1l MQ H2O 
For the preparation of polyacrylamide gels the following protocols were used (see Table 3.24 
and Table 3.25). 
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Table 3.24: Preparation of polyacrylamide separation gels 
8% acrylamide Volume for 2 Gels  
[ml] 
Volume for 4 Gels  
[ml] 
Water 4.6 9.3 
30% Acrylamide mix 2.7 5.3 
Resolving gel buffer  2.5 5 
10% (w/V)  SDS 0.1 0.2 
10% (w/V) APS 0.1 0.2 
TEMED 0.01 0.02 
10% acrylamide 
Water 4 7.9 
30% Acrylamide mix 3.3 6.7 
Resolving gel buffer  2.5 5 
10% (w/V) SDS 0.1 0.2 
10% (w/V) APS 0.1 0.2 
TEMED 0.008 0.012 
12% acrylamide 
Water 3.3 6.6 
30% Acrylamid-Mix 4 8 
Resolving gel buffer  2.5 5 
10% (w/V) SDS 0.1 0.2 
10% (w/V) APS 0.1 0.2 
TEMED 0.08 0.016 
Table 3.25: Preparation of polyacrylamide stacking gels 
Stacking gel Volume for 2 Gels  
[ml] 
Volume for 4 Gels  
[ml] 
Water 2.7 5.5 
30% Acrylamide mix 0.67 1.3 
Stacking gel buffer 0.5 1 
10% (w/V) SDS 0.04 0.08 
10% (w/V) APS 0.04 0.08 
TEMED 0.08 0.016 
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3.4.4 Western Blot 
The method of choice for specific detection of proteins out of complex mixtures was the 
western blot technique. To this end, protein samples separated by SDS PAGE were 
transferred to a nitrocellulose membrane by blotting. In this study, a semi-dry blotting system 
was used. For this purpose, six pieces of Whatman paper, the nitrocellulose membrane and 
the SDS polyacrylamide gel, after electrophoresis, were equilibrated in 1 x blotting buffer and 
arranged in a “sandwich”-like manner. Blotting was performed for 20 min with a constant 
voltage of 20 V. Free protein binding site on the membranes were then blocked in 1xPBST 
containing 5% skim milk for at least 1 h at RT or overnight at 4°C. After three washing steps 
with 1x PBST for 5 min at RT, the primary detection antibody, directed against the POI was 
added and the membrane was incubated for at least 1 h at RT or alternatively overnight at 
4°C. This incubation step was followed by three washing steps performed as before and 
incubation of the membrane with the secondary antibody, which is directed against the 
primary antibody and conjugated with horseradish peroxidase (HRP), for 1 to 2 h at RT. The 
blot was developed by using electro-chemiluminescence ECL detection reagent, which 
contains luminol and hydrogen peroxide. Chemiluminescence is produced by oxidation of 
luminol by HRP conjugated to the secondary antibody and can be detected by using the 
ChemiDoc station or by developing and fixing on chemiluminescence films.  
10 x blotting buffer   58 g/l TRIS-Base     
     29 g/l Glycin      
     3.7 g/l SDS    
1 x blotting buffer   diluted from 10x stock solution ad 800 ml with MQ water 
     + 20% (V/V) methanol ad 1 l 
1 x PBST    1 x PBS  
0.05% Tween (V/V) 
20 x PBS    160 g/l NaCl    pH 7.4 
4 g/l KCl 
15.2 g/l Na2HPO4  ∙ 2 H2O 
4 g/l KH2PO4   
3.4.5 Fibrinogen pulldown assay 
To determine the fibrinogen-binding capacity of proteins, a fibrinogen pulldown assay was 
established in this study. The principle of this method is based on the coupling of the 
investigated proteins to carboxy-activated magnetic Dynabeads followed by the incubation 
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with fibrinogen. By applying a magnetic field, it is possible to isolate fibrinogen bound to 
proteins which were coupled to magnetic beads.  
For this assay, POIs were dialysed against a low pH MES buffer and protein concentration 
was determined. The assay comprises three steps: 1. Activation of magnetic Dynabeads with 
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC); 2. Ligand immobilization; and 3. 
Isolation of the target protein by the fibrinogen pulldown. For activation, 100 µl Dynabeads 
(c0= 10 mg/ml) were incubated with 100 µl of 10 mM NaOH for 5 to 10 min. NaOH was 
removed after applying the magnetic beads to a magnet rack followed by three washing 
steps with 100 µl ddH2O. During the last washing step, EDC was dissolved in cold ddH2O to 
a concentration of 20 mg/ml, 67 µl were added to the Dynabeads and the reaction was 
incubated for 30 min at 4°C with slow tilt rotation. The EDC solution was then removed as 
described above and activated beads were washed with 100 µl ddH2O followed by 100 µl 
MES buffer as quickly as possible to avoid hydrolysis of activated carboxy groups. To couple 
the desired ligand to the Dynabeads, 20 µg of ligand protein were added to the Dynabeads 
and incubated at for 30 min at RT or for 2 h at 4°C with slow tilt rotation. After ligand 
immobilization, beads were washed three times with 300 µl PBS as described before. The 
last step of the assay was the isolation of the target protein by a fibrinogen pulldown. To this 
purpose proteins-coupled Dynabeads were incubated with 50 µg fibrinogen for 30 min at RT 
or 2 h at 4°C with slow tilt rotation. After three washing steps with 300 µl PBS, fibrinogen was 
eluted from the beads by resuspension in 5 x SDS sample buffer and boiling for 5 min at 
95 °C. After centrifugation for 5 min at 13 000 rpm, samples were analyzed by SDS-PAGE. 
MES buffer     25 mM MES   pH 6.0 
250 mM NaCl  
3.4.6 Quantification of proteins 
3.4.6.1 Protein quantification by Bradford assay 
To prepare a calibration curve for the Bradford assay, serial dilutions of BSA protein ranging 
from 0 to 500 µg were prepared in PBS (0, 75, 100, 200, 250, 300, 400 and 500 µl/ml BSA). 
A volume of 10 µl of each BSA concentration was mixed with Bradford reagent, incubated for 
2 to 10 min at RT in the dark and the A595nm was determined. The same procedure was 
applied for the investigated protein sample. Three replicates of each concentration were 
measured for generating the calibration curve. Two replicates of each protein sample were 
measured. Protein concentrations were calculated using the measured A595 data and the 
linear equation of the calibration curve. 
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3.4.7 Dialysis 
Dialysis is a technique to desalt and to exchange buffers in protein solutions. For this 
purpose Servpor® dialysis tubes with a molecular weight cut off (MWCO) corresponding to 
the molecular weight of the POI were used. Dialysis tubes were soaked in MQ water for at 
least 30 min at RT and protein solutions were filled into dialysis tubes and dialysis was 
performed at 4°C against the 10-fold volume of the final buffer with slow stirring. 
3.4.8 Concentration of protein solutions 
For some experiments, high protein concentrations were needed. To increase the 
concentration of protein solutions after purification, Amicon Ultra Centrifugal Filter devices 
with the appropriate MWCO were used. First, centrifugation devices were equilibrated with 
the storing buffer of the protein by adding 10 ml buffer and centrifugation at 4 000 – 
5 000 rpm until the buffer was completely flowed through. To increase the protein 
concentration, protein solutions were loaded onto the centrifugation device and the volume 
was continuously reduced by centrifugation.  
3.5 Biochemical methods 
3.5.1 Measurement of activated partial thromboplastin time (aPTT) 
Activation of the intrinsic pathway of coagulation was determined by measuring the activated 
partial thromboplastin time (aPTT) in murine plasma using a coagulometer. To this end, 50 µl 
of citrated plasma obtained from uninfected and S. pyogenes-infected mice were incubated 
for 60 s at 37°C, 50 µl Kaolin were added followed by another incubation step for 60 s at 
37°C. Clotting was then initiated by the addition of 50 µl CaCl2 solution (25 mM) and the 
coagulation time was measured. 
3.5.2 Fibrinogen conversion experiments  
3.5.2.1 Fibrinogen conversion experiments using purified proteins 
To investigate the final step of the clotting reaction in vitro, the conversion of fibrinogen to 
fibrin was examined. For this purpose, 20 µg purified fibrinogen, 2 µl thrombin reagent and 
5 µg recombinant FXIII were mixed in a total volume of 60 µl and incubated at 37°C for 2 h. 
Reactions were then supplemented with 5 x SDS sample buffer and boiled for 5 min at 95°C. 
Fibrinogen conversion was followed by SDS PAGE and western blot analysis. To investigate 
the influence of several streptococcal M proteins and M protein variants on fibrinogen 
conversion, 0.5 µg or 5 µg of the desired protein were added to the described reactions. 
Sodium citrate (12.9 mM) was used as buffer system for all reactions. 
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Reactions for fibrinogen conversion experiments (total volume/reaction: 60 µl): 
1.) Fibrinogen 
2.) Fibrinogen, Thrombin 
3.) Fibrinogen, Thrombin, FXIII 
4.) Fibrinogen, FXIII 
5.) Fibrinogen, Thrombin, 5 µg M protein variant 
6.) Fibrinogen, Thrombin, 5 µg M protein variant, FXIII 
7.) Fibrinogen, Thrombin, 0.5 µg M protein variant 
8.) Fibrinogen, Thrombin, 0.5 µg M protein variant, FXIII 
9.) 5 µg M protein  
3.5.2.2 Fibrinogen conversion experiments in the presence of bacteria 
S. pyogenes or L. lactis strains were cultured overnight and adjusted to a T600 of 10%. For 
each reaction, 3 ml of bacterial suspension were centrifuged for 4 min at 8 000 rpm and the 
bacterial pellet was resuspended in 100 µl 12.9 mM sodium citrate buffer. Reactions were 
prepared as following:  
1. 100 µl  Bacterial suspension   
100 µl Fibrinogen (final concentration 0.3 mg/ml) 
      5 µl  Thrombin 
2. 100 µl  Bacterial suspension   
100 µl Fibrinogen (final concentration 0.3 mg/ml) 
5 µl  Thrombin 
10 µl  FXIII (final concentration 0.05 mg/ml) 
 
3. 100 µl  Bacterial suspension  
100 µl  Fibrinogen (final concentration 0.3 mg/ml) 
4. 35 µl  Fibrinogen (final concentration 0.3 mg/ml) 
2 µl  Thrombin 
23 µl  Sodium citrate 
5. 35 µl  Fibrinogen (final concentration 0.3 mg/ml) 
2 µl  Thrombin 
5 µl  FXIII (final concentration 0.05 mg/ml) 
23 µl  Sodium citrate 
controls 
controls 
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After incubation for 30 min at 37°C, 5 x SDS sample buffer was added and samples were 
boiled at 95°C for 10 min. Fibrinogen conversion was followed by SDS PAGE and western 
blot analysis. 
3.6 Mouse strains and infection model 
3.6.1 Mouse stains 
Wild type and FXIII-deficient mice in the CBA/Ca background were used in this study. 
CBA/Ca wild type mice were purchased from Harlan (Venray, The Netherlands). FXIII-
deficient animals (FXIII-/-) were kindly provided by CSL Behring (Marburg, Germany). Mice 
were housed in a pathogen-free animal facility at the Helmholtz Centre for Infection 
Research and maintained under standard conditions according to institutional guidelines. All 
experiments were approved by the appropriate ethical committee for animal experimentation 
(Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit, 
Oldenburg, Germany; permit 33.9-42502-04-12/1009). 
3.6.2 Animal infection model 
For in vivo experiments, 8 to 12 week old female wild type or FXIII-/- mice were 
subcutaneously inoculated with 5 x 107 CFU S. pyogenes strain 5448 on the back. In some 
experiments, mice were treated with 200 U/kg body weight of a human FXIII-concentrate 
Fibrogammin®P subcutaneously at the site of infection 1 h after bacterial inoculation. Mice 
were monitored and weighted daily after infection and mortality was recorded for generating 
survival curves. At indicated time points mice were sacrificed, citrated blood was drawn by 
cardiac puncture and centrifuged for 10 min at 5000 rpm to prepare plasma for 
immunological approaches or for the measurement of clotting times. Skin biopsies from the 
local focus of infection were obtained for histological examination or double 
immunofluorescence analysis. Spleens and livers were dissected for the determination of 
bacterial loads at 72 h of infection. For this purpose, spleens and livers were homogenized in 
5 ml of PBS using a Polytron disperser and 10-fold serial dilutions of the organ homogenates 
as well as blood samples were plated onto blood agar. The number of bacteria was 
determined by counting colonies after 18 h of incubation at 37°C. 
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3.7 Immunological methods 
3.7.1 Enzyme-linked immunoabsorbant assay (ELISA) 
3.7.2 Interleukin-6 ELISA  
The level of IL-6 in the plasma of uninfected or S. pyogenes-infected mice was measured by 
using the Mouse IL-6 ELISA MAX™ Standard kit according to the manufacturer’s 
instructions. Plasma samples were diluted 1:4 in PBS supplemented with 0,05% Tween 20 
prior to incubation. 
3.7.3 Histopathology 
Histological analysis of skin samples was used to determine the distribution of bacteria at the 
site of infection and to investigate the degree of tissue damage. All histological examinations 
were kindly performed by Dr. Marina Pils (Mouse pathology, Animal Experimental Unit, HZI). 
Skin samples obtained from uninfected and S. pyogenes-infected mice were fixed in 4% 
neutrally buffered formaldehyde and embedded in paraffin according to standard histological 
procedures. Sections of 3 µm thickness were stained with hematoxylin-eosin (HE) and 
evaluated by light microscopy blinded to the experimental groups. Inflammation was graded 
in the different parts of the skin (dermis, panniculum, subcutis) from 0 = no inflammation, 1 = 
few inflammatory infiltrates, 2 = moderate, clearly visible inflammatory infiltrates, 3 = severe 
inflammatory infiltrates with tissue destruction and 4 =for extreme inflammation leading to 
tissue destruction and causing necrosis. 
3.8 Microscopy techniques 
3.8.1 Immunofluorescence microscopy 
Immunofluorescence microscopy was used to verify the heterologous expression of 
streptococcal M1 protein and chimeric M protein variants on the surface of L. lactis. 
L. lactis strains were cultured overnight as described above and 250 to 500 µl overnight 
culture were centrifuged for 4 min at 5 000 rpm. The resulting bacterial pellet was incubated 
with the primary antibody against the streptococcal M1 protein diluted 1:100 in 50µl PBS with 
10% (V/V) FCS for 45 min at 37°C. Bacterial cells were washed twice with 150 µl PBS, the 
bacterial pellet was resuspended in 50 µl PBS with 10% (V/V) FCS containing the secondary 
anti-rabbit antibody conjugated with Alexa 488 (dilution 1:200) and incubated for 45 min at 
37°C with occasionally mixing. Bacteria were washed three times with 150 µl PBS and fixed 
in 50 µl 4% paraformaldehyde (PFA). Cell nuclei were stained by mixing 3 µl of the sample 
with 1 µl Fluoroshield™ with DAPI on a microscope slide. Cover slips were then placed on 
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the microscope slide and samples were dried in a “wet-chamber” overnight at 4°C or 1 h at 
RT in the dark. Samples were analyzed using the fluorescence microscope Zeiss Axio 
Imager A2. 
3.8.2 Double immune fluorescence microscopy  
Double immune fluorescence microscopy analysis was kindly performed by Bhavya 
Chakrakodi and Dr. Linda Johansson from the Center for Infectious Medicine, Department of 
Medicine, Karolinska Institute, Karolinska University Hospital Huddinge (Stockholm, 
Sweden). For fluorescence microscopy skin samples obtained from uninfected and S. 
pyogenes infected mice were snap-frozen in liquid nitrogen. The biopsies were then 
cryosectioned to 8 μm, fixed in 2% formaldehyde and immunofluorescent stainings of serial 
sections were conducted as described previously (Thulin et al., 2006). For 
immunefluorescence staining the following antibodies were used: rabbit polyclonal anti-factor 
XIIIa and goat polyclonal anti-Streptococcus pyogenes group A as well as Alexa 488 
conjugated donkey-anti-rabbit IgG and Alexa 647 conjugated donkey-anti-goat IgG. Slides 
were mounted using DAPI supplemented mounting media. The stained sections were 
examined using a Nikon A1R confocal microscope. 
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4 RESULTS 
4.1 Role of a FXIII-mediated innate immune mechanism in host defense 
against S. pyogenes 
Recent studies have provided evidence supporting a role for the coagulation system in the 
innate immune response against S. pyogenes. Experimental results demonstrated that the 
contact system is activated on the surface of pathogenic bacteria including S. pyogenes, 
E. coli and S. aureus through specific interactions of contact factors with bacterial surface 
proteins. The initial contact activation induces the entire clotting cascade and leads to the 
immobilization of these bacteria within the newly formed fibrin networks (Herwald et al., 
2003; Wang et al., 2010; Loof et al., 2011b). The role of this innate immune mechanism in 
the host defense against S. pyogenes and in limitation of systemic bacterial spreading has 
been investigated within the context of this study. 
4.1.1 Bacterial entrapment within fibrin clots is not effective against all 
Streptococcus species 
To determine the capacity of the fibrin network to entrap different bacterial species belonging 
to the genus Streptococcus including S. pyogenes of serotype M1, SDSE of serotype stG11 
as well as S. oralis and S. pneumoniae, in vitro clotting experiments were performed. 
Bacteria were adjusted to a transmission at 600 nm (T600) of 10% representing approximately 
5 x 108 CFU/ml and were further diluted in sodium citrate buffer. Finally, approximately 5 x 
105 CFU (log10 5.7) bacteria were used per in vitro clotting reaction (inoculum, indicated as 
“w/o plasma” in Figure 4.1). Bacteria were mixed with normal human plasma and clotting was 
induced by the addition of thrombin. After fibrin network formation, clots were covered with 
1% of normal human plasma. The supernatant, which contains the bacteria that are not 
associated with the fibrin network, was plated and the amount of immobilized bacteria was 
calculated by comparing the amount of bacteria in the supernatant with the amount of 
bacteria originally inoculated in these experiments.  
The results shown in Figure 4.1 demonstrated that S. pyogenes M1 and SDSE but not 
S. oralis or S. pneumoniae were entrapped within fibrin networks. Thus, whereas the amount 
of S. pyogenes and SDSE was significantly reduced in the clot supernatant compared to the 
amount of originally inoculated bacteria, no differences were observed between the amount 
of S. oralis and S. pneumoniae in the clot supernatant and the amount of bacteria in the 
original inoculum (Figure 4.1). These observations lead to the conclusion that neither 
S. oralis nor S. pneumoniae were entrapped in fibrin clots. 
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Figure 4.1: Entrapment of different species belonging to the genus Streptococcus within 
fibrin clots.  
S. pyogenes M1, SDSE as well as S. oralis and S. pneumoniae were investigated for 
their initial interactions with the fibrin network by in vitro clotting assays using normal 
human plasma. Bacterial loads detected in the clot supernatant (black bars) were 
compared to bacterial loads that were originally inoculated in these assays (white 
bars). The graphs represent the mean ± SD of at least three independent experiments. 
Statistical significance was calculated by ANOVA, *** p < 0,001. 
 
The results presented in Figure 4.1 clearly demonstrated the effective entrapment of 
S. pyogenes and SDSE during in vitro clotting. Since previous studies reported that bacterial 
cross-linking within fibrin networks is mediated by interactions between bacterial surface 
structures and coagulation factors, the role of the major surface proteins of S. pyogenes and 
SDSE in bacterial entrapment was investigated. For this purpose, the initial interactions of 
S. pyogenes and SDSE wild type and corresponding mutant strains lacking their surface 
proteins M1 and stG11 (also known as FOG), respectively, were analyzed. The 
immobilization of the S. pyogenes and SDSE mutant strains was significantly reduced when 
compared with their corresponding wild type strains indicating a role of these surface 
proteins during the entrapment process (Figure 4.2 and 4.3). However, by comparing the 
bacterial CFU in the clot supernatant with that in the inoculum, the entrapment of these 
mutant strains was not completely abolished. These observations lead to the suggestion that 
1
2
3
4
5
6
7
L
o
g
10
 C
F
U
 b
ac
te
ri
a 
p
er
 m
l 
su
p
er
n
at
an
t
w/o plasma
plasma + 
thrombin
*** 
*** 
*** 
*** 
*** *** 
RESULTS 
61 
 
also other surface structures of S. pyogenes and SDSE influence their interactions with the 
fibrin network.  
 
 
Figure 4.2: Contribution of M1 protein to the entrapment of S. pyogenes of serotype M1. 
S. pyogenes M1 wild type and the corresponding mutant strain lacking the M1 protein 
(S. pyogenes ΔM1) were investigated for their initial interactions with the fibrin network 
by in vitro clotting assays using normal human plasma. (A) Bacteria CFU in the clot 
supernatants of S. pyogenes wild type and ΔM1. The graphs represent the mean ± SD 
of at least three independent experiments. Statistical significance was calculated by T 
test: ** p < 0.01.  
Scanning electron micrographs of the immobilization of S. pyogenes M1 wild type (B) 
and S. pyogenes ΔM1 (C) within fibrin clots. Bacteria are indicated by red arrows. 
The M1 protein-dependent entrapment of S. pyogenes M1 and the FOG protein-dependent 
entrapment of SDSE stG11 were confirmed by scanning electron microscopy. The 
photographs depicted in Figure 4.2 B and Figure 4.3 B show the efficient immobilization of 
S. pyogenes M1 and SDSE wild type bacteria within the fibrin network represented by tightly 
enwoven bacteria. The entrapment of S. pyogenes and SDSE mutant strains lacking the 
surface M1 (Figure 4.2 C) or the FOG (Figure 4.3 C) protein is strongly reduced in 
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comparison to the wild type strains, supporting the suggestion of a contribution of these 
surface proteins during clot entrapment. 
 
 
Figure 4.3: Contribution of M-like protein stG11 (FOG protein) to the entrapment of SDSE. 
SDSE and the corresponding mutant strain lacking the FOG protein (SDSE ΔstG11) 
were investigated for their initial interactions with the fibrin network by in vitro clotting 
assays using normal human plasma. (A) Bacteria CFU in the clot supernatants of 
SDSE wild type and SDSE ΔstG11. The graphs represent the mean ± SD of at least 
three independent experiments. Statistical significance was calculated by T test: *** p 
< 0,001. Scanning electron micrographs of the immobilization of SDSE wild type (B) 
and SDSE ΔstG11 (C) within fibrin clots, respectively. Bacteria are indicated by red 
arrows. 
 
Taken together, the results of the in vitro clotting assays and scanning electron microscopy 
analysis using different species of the genus Streptococcus suggest that the bacterial 
entrapment is limited to certain species such as S. pyogenes and SDSE and that bacterial 
immobilization within fibrin clots seems to be largely mediated by M or M-like proteins in 
these bacterial species. 
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4.1.2 The role of FXIII in the entrapment of streptococci within fibrin networks 
is limited to S. pyogenes of the M1 serotype 
FXIII was previously identified as the key component of the coagulation cascade that 
mediates the immobilization of different pathogenic bacteria, including S. pyogenes, within 
fibrin clots (Wang et al., 2010; Loof et al., 2011b). By interacting with streptococcal surface 
proteins such as the M1 protein, activated FXIII (FXIIIa) mediates the entrapment of 
S. pyogenes (Loof et al., 2011b).  
To investigate the role of FXIII in the entrapment of streptococci within the fibrin clot, in vitro 
clotting assays using S. pyogenes bacteria of different M serotypes as well as a SDSE strain 
were performed using normal and FXIII-deficient plasma. For these assays, bacteria were 
adjusted and diluted as mentioned before. Thus, the mean value of the bacteria inoculated in 
these assay was 6,12 +/-0,43 log10 CFU. While the entrapment of S. pyogenes of serotype 
M1 was significantly influenced by FXIII, the immobilization of S. pyogenes of serotypes M1-
2, M3, M6, M49 and M53 as well as SDSE was not significantly influenced by FXIII (Figure 
4.4). Although the bacterial CFU of S. pyogenes M1-2, M3, M6, M49 and M53 as well as 
SDSE within the supernatant of FXIII-deficient plasma clots was slightly increased compared 
to normal plasma, the difference did not reach statistic significance. These data indicate that 
the contribution of FXIII to the entrapment within the fibrin network is limited to S. pyogenes 
of M1 serotype (Figure 4.4).  
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Figure 4.4: Entrapment of S. pyogenes of different M serotypes in the presence or absence 
of FXIII. 
Bacterial CFU in the clot supernatant of different S. pyogenes M serotype strains 
during in vitro clotting using normal (black bars) and FXIII-deficient human plasma 
(white bars). The graphs represent the mean ± SD of at least three independent 
experiments. Statistical significance was calculated by T test: * p < 0.05. 
The influence of FXIII on the entrapment of S. pyogenes bacteria of the serotype M1 was 
also confirmed by scanning electron microscopy using the S. pyogenes strain AP1 (Figure 
4.5). Large amounts of S. pyogenes AP1 bacteria were found tightly enwoven within plasma 
clots generated from normal plasma (Figure 4.4 A). In contrast, only single bacteria were 
loosely associated with the fibrin network generated from FXIII-deficient plasma as shown in 
Figure 4.5 B. 
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Figure 4.5:  Entrapment of S. pyogenes bacteria of serotype M1 is influenced by FXIII. 
Scanning electron micrographs showing the immobilization of S. pyogenes M1 strain 
AP1 within fibrin networks generated from normal (A) and FXIII-deficient (B) human 
plasma (photos taken from Loof, Deicke and Medina, 2014). Bacteria are indicated by 
red arrows. 
To further confirm the relevance of FXIII in the fibrin-mediated immobilization of S. pyogenes 
M1 bacteria, the entrapment of different wild type S. pyogenes M1 strains (AP1and 5448) 
and their corresponding M1-deficient isogenic mutant strains was investigated in the 
presence and absence of FXIII. The mean value of the bacteria inoculated in these assays 
was 6,11 +/- 0,3 log10 CFU. Significant higher amounts of AP1 and 5448 bacteria were 
detected in the supernatant of FXIII-deficient human plasma when compared to normal 
human plasma (Figure 4.6). These results confirmed the less effective entrapment of 
S. pyogenes M1 bacteria in the absence of FXIII. Moreover, it was noted that the amount of 
bacteria in the supernatant was also significantly higher when the entrapment of the M1-
deficient mutant strains was compared to that of the wild type strains in normal plasma 
(Figure 4.6). If both, the streptococcal M1 protein and FXIII are missing nearly the whole 
bacterial inoculum used for the assay, was detected in the supernatant indicating that the 
bacterial entrapment was nearly but not completely abolished without FXIII and the M1 
protein (Figure 4.6).  These results demonstrated the relevance of FXIII and the M1 protein 
for fibrin immobilization of S. pyogenes but also indicate the contribution of additional factors 
in the entrapment process.  
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Figure 4.6:  Entrapment of S. pyogenes of serotype M1 within fibrin clots is influenced by 
FXIII and streptococcal M1 protein. 
Bacterial CFU in the clot supernatant of different S. pyogenes M1 serotype strains 
during in vitro clotting. Amounts of S. pyogenes AP1 and 5448 wild type bacteria as 
well as their corresponding M1-deficient mutant strains in the presence of normal 
(black bars) or FXIII-deficient (white bars) plasma are shown. The graphs represent 
the mean ± SD of at least three independent experiments. Statistical significance was 
calculated by T test: * p < 0.05 and ** p < 0.01. 
4.2 Molecular mechanism underlying the FXIII-mediated entrapment of 
S. pyogenes M1 bacteria within the fibrin network 
Published data (Loof et al., 2011b) as well as experiments performed within the context of 
this thesis demonstrated a contribution of FXIII to the immobilization of S. pyogenes M1 
bacteria within fibrin clots. As an interaction between FXIII and the streptococcal M1 protein 
was previously shown using immunofluorescence microscopy and transmission electron 
microscopy (Loof et al., 2011b), the possibility of a covalent linkage between the 
streptococcal M1 protein and FXIII was investigated in this study. For this purpose, fibrinogen 
conversion assays were established by mixing purified fibrinogen, thrombin and FXIII in 
different reactions and incubating them for 2 h at 37°C to allow fibrin formation. The 
conversion of fibrinogen to fibrin in this assay was determined by SDS PAGE and 
fibrin(ogen) western blot analysis.  
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Denatured fibrinogen, separated by SDS PAGE, is characterized by three protein bands of 
approximately 65 kDa, 52 kDa and 46 kDa representing the α-, β- and γ-chains of fibrinogen, 
respectively (Figure 4.6; Weisel, 2005). The addition of thrombin to fibrinogen mediates the 
conversion to fibrin that can be followed by the formation of a protein band of approximately 
95 kDa representing the fibrin γ-γ dimers (Figure 4.7). The incubation of fibrinogen with FXIII 
did not alter the band pattern of fibrinogen, while incubation of fibrinogen with thrombin and 
FXIII resulted in cross-linked fibrin polymers characterized by the generation of γ-γ dimer 
bands and high molecular α polymer bands (Figure 4.7). The sample containing thrombin 
and FXIII served as a control. The results of these first experiments illustrated that this assay 
was suitable to analyze fibrinogen conversion in vitro. 
 
 
Figure 4.7: In vitro conversion of fibrinogen to fibrin. 
The conversion of fibrinogen to fibrin in vitro was analyzed by SDS PAGE (A) and 
western blot against fibrin(ogen) (B). PageRuler Prestained Protein Ladder was used 
as a molecular weight standard (M). Protein samples were diluted in a 1:10 ratio with 
1 x SDS sample buffer for the western blot analysis. Fbg: fibrinogen; Thr: thrombin; 
FXIII: factor XIII; γ-γ: fibrin γ-γ dimers; (α)n: fibrin α polymers. 
4.2.1 Streptococcal M1 protein inhibits the fibrinogen conversion to fibrin 
To analyze the interactions between the streptococcal M1 protein with fibrinogen and FXIII, 
fibrinogen conversion assays were performed in the presence of recombinant streptococcal 
M1 protein (Figure 4.8). In contrast to the hypothesis, no covalent complexes between the 
M1 protein and FXIII were observed by SDS PAGE and fibrin(ogen) blot after in vitro clotting 
reaction. Thus, no γ-γ dimers were observed after incubation of fibrinogen with thrombin in 
the presence of 0.5 µg as well as 5 µg of M1 protein, indicating that the conversion to fibrin 
was inhibited (Figure 4.8). However, when FXIII was added to fibrinogen, thrombin and M1 
protein, fibrin γ-γ dimers as well as fibrin α polymers were detected again (Figure 4.8).  
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Figure 4.8: Fibrinogen conversion in vitro in the presence of streptococcal M1 protein. 
 The conversion of fibrinogen to fibrin in vitro in the presence of 0.5 and 5 µg of 
streptococcal M1 protein was analyzed by SDS PAGE and Coomassie staining (A) as 
well as by western blot analysis using anti-fibrin(ogen) antibody (B). PageRuler 
Prestained Protein Ladder was used as a molecular weight standard (M). Protein 
samples were diluted in a 1:10 ratio with 1 x SDS sample buffer for the western blot 
analysis. Fbg: fibrinogen; Thr: thrombin; FXIII: factor XIII; M1: streptococcal M1 
protein; γ-γ: fibrin γ-γ dimers; (α)n: fibrin α polymers. 
The results of these experiments lead to the interesting observation that the M1 protein was 
able to inhibit the fibrinogen conversion to fibrin during in vitro clotting. However, addition of 
FXIII was able to revert the inhibitory effect of M1 protein and fibrin was generated. These 
data suggest that FXIII could counteract the inhibitory effects of the M1 protein during fibrin 
formation. 
To clarify if the inhibitory effect of the fibrin formation was an exclusive feature of the M1 
protein or if it is also mediated by other M proteins, fibrinogen conversion assays were 
performed in the presence of recombinant streptococcal M1-2, M3 and M55 protein as well 
as the M-like protein FOG of SDSE (Figure 4.9). The M1-2, M3, M55 and the FOG proteins 
failed to inhibit fibrinogen conversion in the absence and in the presence of FXIII as indicated 
by the formation of γ-γ dimers as well as fibrin α polymers (Figure 4.9). These results indicate 
that only the streptococcal M1 protein was able to inhibit the fibrin formation. However, this 
inhibitory effect was reverted in the presence of FXIII. 
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Figure 4.9:  Fibrinogen conversion in vitro in the presence of different streptococcal M and 
M-like proteins. 
 The conversion of fibrinogen to fibrin in vitro in the presence of 5 µg streptococcal  
M1-2 (A), M3.23 (B), M55 (C) and FOG (D)  protein was analyzed by SDS PAGE and 
Coomassie staining. PageRuler Prestained Protein Ladder was used as a molecular 
weight standard (M). Fbg: fibrinogen; Thr: thrombin; FXIII: factor XIII; M1: 
streptococcal M1 protein; γ-γ: fibrin γ-γ dimers. 
4.2.2 The hypervariable A region within the streptococcal M1 protein is 
responsible for the inhibition of fibrinogen conversion 
To further delineate the region of the M1 protein responsible for the inhibitory effect, different 
constructs containing different domains of the M1 protein were generated and used in 
fibrinogen conversion experiments (Figure 4.10) 
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Figure 4.10:  Overview of the M1 protein constructs and chimeric M proteins. 
Schematic representation of the constructs containing the different M1 protein 
domains as well as the chimeric M proteins A1M3 and A3M1. Yellow: A1 region; 
green: B repeat region; violet: S region; blue: C repeat region; red: D repeat region; 
orange: A3 region.  
M1 protein constructs containing the N terminal domains (the ABs construct) and the C 
terminal domains (the sCD construct) were compared with the full-length M1 protein for their 
capacity to inhibit fibrinogen conversion (Figure 4.11). Whereas the ABs construct containing 
the fibrinogen-binding regions exhibited a similar capacity as the full-length M1 protein to 
inhibit the fibrin formation in the absence of FXIII, the sCD construct did not affect fibrin 
formation (Figure 4.11). Thus, using this experimental approach, the N terminal part of the 
M1 protein was identified as responsible for the inhibition of fibrin formation. 
To further identify the domain within the N terminal part of the M1 protein responsible for the 
inhibitory effect, constructs containing either the A region or the B repeat region of the M1 
protein were tested in fibrinogen conversion assays (Figure 4.11). Interestingly, the B repeat 
region, which represents the classical fibrinogen binding domain within the M1 protein, was 
incapable to inhibit the fibrinogen conversion to fibrin, neither in the presence nor in the 
absence of FXIII (Figure 4.11). However, the small A region of the streptococcal M1 protein 
alone was able to inhibit fibrin formation, but only in the absence of FXIII (Figure 4.10).  
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Figure 4.11: Capacity of the different M1 protein domains to inhibit fibrinogen conversion. 
 The conversion of fibrinogen to fibrin in vitro in the presence of 5 µg streptococcal M1 
protein constructs was analyzed by SDS PAGE and Coomassie staining (A) as well as 
western blot analysis using anti-fibrin(ogen) antibody (B). PageRuler Prestained 
Protein Ladder was used as a molecular weight standard (M). Protein samples were 
diluted in a ratio 1:10 with 1 x SDS sample buffer for western blot analysis. Fbg: 
fibrinogen; Thr: thrombin; FXIII: factor XIII; M1: streptococcal M1 protein; A: M protein 
A region; B: M protein B repeat region; ABs: M protein construct containing the N 
terminal A, B and S region; sCD:  M protein construct containing the C terminal S, C 
and D region; γ-γ: fibrin γ-γ dimers; (α)n: fibrin α polymers. 
To confirm the results described above, fibrinogen conversion experiments were performed 
in the presence of recombinant chimeric M proteins as a proof of concept. To generate these 
chimeras, the A regions of the M1 and the M3 protein were exchanged resulting in the 
chimeric proteins A1M3, representing a M3 protein containing the A region of the M1 protein, 
and A3M1, representing a M1 protein containing the A region of the M3 protein. As shown in 
Figure 4.12, the A1M3 but not the A3M1 protein was capable to inhibit the fibrin formation in 
the absence of FXIII. The ability of the M1 protein to inhibit the fibrin formation in the absence 
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of FXIII was lost if only the A region was exchanged against the A region of the M3 protein. 
However, fibrinogen conversion was detected in the presence of the A1M3 protein after 
addition of FXIII (Figure 4.12).  
 
 
Figure 4.12: Fibrinogen conversion in vitro in the presence of the chimeric streptococcal M 
protein constructs A1M3 and A3M1. 
 The conversion of fibrinogen to fibrin in vitro in the presence of 0.5 and 5 µg A1M3 (A) 
and A3M1 (B) M protein constructs was analyzed by was analyzed by SDS PAGE and 
Coomassie staining. As a molecular weight standard (M) the PageRuler Prestained 
Protein Ladder was used. Fbg: fibrinogen; Thr: thrombin; FXIII: factor XIII; M1: 
streptococcal M1 protein; γ-γ: fibrin γ-γ dimers. 
4.2.3 The A region of the streptococcal M1 protein binds fibrinogen 
The ability of streptococcal M proteins to bind fibrinogen was already described in 1933 by 
Tillet and Garner (Tillett and Garner, 1933). In 2000, the M protein B repeat region was 
identified as the fibrinogen-binding domain within the M protein (Ringdahl et al., 2000). 
Interestingly, the results described above demonstrate that the A region of the streptococcal 
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M1 protein was responsible for the inhibition of the fibrinogen conversion. These 
observations lead to the suggestion that fibrinogen-binding is perhaps a precondition for the 
inhibition of the fibrin formation. Therefore, the fibrinogen binding capacity of the A region of 
the M1 protein was investigated in fibrinogen pulldown experiments (Figure 4.13).  
To this end, different constructs representing the different domains of the M1 protein were 
covalently coupled to magnetic beads followed by incubation with fibrinogen as described in 
section 3.4.5. Fibrinogen bound to magnetic beads coated with either the full-length M1 
protein, the A region or the B repeat region was eluted and visualized by SDS-PAGE (Figure 
4.13). The results revealed that, besides the classical fibrinogen-binding B repeat region, 
also the A region has the capacity to bind fibrinogen. This was clearly indicated by the 
detection of fibrinogen within the elution fractions (Figure 4.13). The sCD construct served as 
a negative control (Figure 4.13). The identity of the eluted proteins was confirmed by western 
blot analysis against fibrin(ogen) (data not shown).  
 
 
Figure 4.13: Fibrinogen binding capacity of the different M1 protein domains. 
Fibrinogen pulldown assays using either the full-length M1 protein, the A region, the B 
repeat region or the sCD construct were analyzed by SDS PAGE and Coomassie 
staining. PageRuler Prestained Protein Ladder was used as a molecular weight 
standard (M). S: supernatant; W1 – 3: washing fractions; E: eluate; B: beads after 
elution; α, β, γ: α, β, γ chains of fibrinogen. 
The results of the fibrinogen pulldown assay demonstrated the capacity of the A region of the 
streptococcal M1 protein to bind fibrinogen. These results are in accordance with a recent 
study reported by Macheboeuf and colleagues (Macheboeuf et al., 2011). Hence, besides 
the B repeat region also the A region contributes to fibrinogen-binding of the M1 protein. 
These observations suggest that the fibrinogen binding capacity of the A region may be 
related to its ability to inhibit the fibrinogen conversion in vitro. 
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4.2.4 S. pyogenes of serotype M1 mediates the inhibition of fibrinogen 
conversion in vitro 
The previously described data were derived from in vitro fibrinogen conversion experiments 
using recombinant M proteins and M protein constructs. Therefore, the capacity of 
S. pyogenes M1 to influence the fibrinogen conversion in vitro was investigated in fibrinogen 
conversion experiments using whole bacteria (see section 3.5.3.2).  
Similar to the results with the recombinant protein, S. pyogenes M1 strain AP1 inhibited the 
conversion of fibrinogen to fibrin in the absence of FXIII (Figure 4.14). Thus, the protein band 
around 95 kDa representing the γ-γ dimer was absent in the SDS PAGE in the presence of 
S. pyogenes AP1 (Figure 4.14). In contrast, when S. pyogenes MC25, the isogenic mutant 
strain lacking the M1 protein was used, the in vitro fibrin formation was not affected and the 
γγ-dimers were observed (Figure 4.14). The γ-γ dimers of fibrin were also detected in the 
presence of the S. pyogenes M3 strain A600, which accordingly did not influence the fibrin 
formation in vitro (Figure 4.14). These observations support the previous results that only the 
M1 protein has the ability to suppress fibrin formation. Western Blot analysis against 
fibrin(ogen) confirmed the results of the SDS PAGE (data not shown). 
 
 
 
Figure 4.14: Fibrinogen conversion in vitro in the presence of S. pyogenes. 
The conversion of fibrinogen to fibrin in vitro in the presence of S. pyogenes AP1 (M1), 
MC25 (ΔM1) and A600 (M3) was analyzed by SDS PAGE and Coomassie staining. 
As a molecular weight standard (M) the PageRuler Prestained Protein Ladder was 
used. Fbg: fibrinogen; Thr: thrombin; FXIII: factor XIII; γ-γ: fibrin γ-γ dimers, ctr.: 
controls without bacteria. 
To confirm that the fibrinogen conversion is also inhibited by other S. pyogenes strains of 
serotype M1, experiments were performed using the M1 strains 90-226 and 5448 as well as 
their corresponding M1 deficient mutant strains (90-226 ΔM1 and 5448 ΔM1). Indeed, similar 
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to the observation obtained from experiments with strain AP1 (Figure 4.14), fibrin formation 
was also inhibited by S. pyogenes M1 wild type strains 90-226 and 5448 in the absence of 
FXIII but not by the corresponding mutant strains lacking the M1 protein (Figure 4.15).  
 
 
 
Figure 4.15: Fibrinogen conversion in vitro in the presence of S. pyogenes serotype M1. 
The conversion of fibrinogen to fibrin in vitro in the presence of S. pyogenes 5448 and 
its corresponding M1-deficient mutant strain (5448ΔM1) (A) as well as S. pyogenes 
90-226 and the corresponding mutant strain 90-226 ΔM1 (B) were analyzed by SDS 
PAGE and Coomassie staining. PageRuler Prestained Protein Ladder was used as a 
molecular weight standard (M). Fbg: fibrinogen; Thr: thrombin; FXIII: factor XIII; γ-γ: 
fibrin γ-γ dimers, ctr.: controls without bacteria. 
Taken together, the results of fibrinogen conversion experiments using different S. pyogenes 
strains are in good agreement with the observations from experiments using recombinant M 
proteins. The data suggest that M1 protein either recombinantly produced and purified or 
expressed on the bacterial surface is able to inhibit the fibrin formation. 
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4.2.5 Heterologous expressed streptococcal M1 protein on the surface of 
L. lactis inhibits fibrinogen conversion 
Since in addition to the M protein, S. pyogenes expresses several surface-associated 
proteins that can interact with fibrinogen, a heterologous expression system was used to 
confirm the exclusivity of M1 protein in the inhibition of fibrinogen conversion. For this 
purpose, non-pathogenic L. lactis strains heterologous expressing the streptococcal M1 
protein and chimeric M protein constructs A1M3 and A3M1 on their surface were generated. 
Because L. lactis bacteria do not express surface proteins capable to interact with fibrinogen, 
any effect on the fibrinogen conversion observed with the generated L. lactis strains can be 
solely attributed to the action of the heterologous expressed M proteins.  
The expression of the M1 protein as well as the chimeric M proteins, A1M3 and A3M1, on 
the surface of L. lactis was visualized by immunofluorescence microscopy (Figure 4.16). For 
this purpose, L. lactis bacteria were prepared as described in section 3.8.1 and incubated 
with a specific primary antibody against the M1 protein followed by a green fluorescence-
conjugated secondary antibody. Green fluorescence was only detected if L. lactis strains 
expressed the M1 protein or the chimeric proteins A1M3 and A3M1 on the bacterial surface. 
Thus, it was verified that the generated L. lactis strains expressed the M proteins mentioned 
above since only these strains but not the L. lactis wild type strain exhibited green 
fluorescence under microscopic examination (Figure 4.16). The cell nuclei were stained with 
DAPI in blue to visualize bacteria in all samples. 
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Figure 4.16: Heterologous expression of streptococcal M proteins on the surface of L. lactis. 
 Immunofluorescence microscopy analysis of L. lactis wild type bacteria (A) and 
L. lactis strains expressing the streptococcal M1 protein (B), the A1M3 protein (C) and 
the A3M1 protein (D) on their surface, stained with a specific primary antibody against 
the M1 protein and a green fluorescence-conjugated secondary antibody (green). Cell 
nuclei were stained with DAPI (blue).   
The L. lactis wild type and M protein-expressing strains were then used in fibrinogen 
conversion experiments. The results from the SDS PAGE and western blot analysis 
presented in Figure 4.17 show that while fibrin formation was not influenced by L. lactis wild 
type bacteria, L. lactis strain expressing the streptococcal M1 protein on its surface was 
capable to inhibit fibrinogen conversion in the absence of FXIII. This was demonstrated by 
the absence of γ-γ dimer bands in these samples (Figure 4.17). These data indicate that 
heterologous expressed streptococcal M1 protein is also able to inhibit the fibrin formation in 
vitro. To confirm this further, the red labeled protein bands were analyzed via mass 
spectrometry and identified as fibrin γ-γ dimers (data not shown).  
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Figure 4.17:  Fibrinogen conversion in the presence of L. lactis strains. 
 The conversion of fibrinogen to fibrin in vitro in the presence of L. lactis wild type and 
L. lactis expressing streptococcal M1 protein was analyzed by SDS PAGE and 
Coomassie staining (A) as well as western blot analysis using anti-fibrin(ogen) 
antibody (B). PageRuler Prestained Protein Ladder was used as a molecular weight 
standard (M). Protein samples were diluted in a ratio 1:25 with 1 x SDS sample buffer 
for the western blot analysis. Fbg: fibrinogen; Thr: thrombin; γ-γ: fibrin γ-γ dimers. 
Furthermore, fibrinogen conversion experiments using L. lactis mutant strains expressing the 
chimeric M protein constructs confirmed the importance of the A region of the M1 protein for 
the inhibition of fibrinogen conversion. In the absence of FXIII, the L. lactis strain expressing 
the A1M3 protein inhibited fibrin formation (Figure 4.18). Nevertheless, in the presence of 
FXIII, fibrinogen was converted to fibrin as shown by the presence of the γ-γ dimer and α 
polymers. In contrast, the L. lactis strain expressing the A3M1 protein did not influence the 
fibrin formation neither in the presence nor in the absence of FXIII (see Figure 4. 18).  
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Figure 4.18: Fibrinogen conversion in vitro in the presence of L. lactis expressing A1M3 and 
A3M1. 
 The conversion of fibrinogen to fibrin in vitro in the presence of L. lactis strains 
expressing the A1M3 or the A3M1 protein was analyzed by SDS PAGE and 
Coomassie staining (A) as well as western blot analysis using anti-fibrin(ogen) 
antibody (B). PageRuler Prestained Protein Ladder was used as a molecular weight 
standard (M). Protein samples were diluted in a ratio 1:15 with 1 x SDS sample buffer 
for the western blot analysis. Fbg: fibrinogen; Thr: thrombin; FXIII: factor XIII; M1: 
streptococcal M1 protein; γ-γ: fibrin γ-γ dimers; (α)n: fibrin α polymers. 
In conclusion, the results obtained from the experiments using L. lactis bacteria suggest that 
the streptococcal M1 protein and the A region of this protein were able to inhibit the 
fibrinogen conversion to fibrin in vitro also when they were expressed on the surface of non-
pathogenic bacteria.  
4.3 Role of FXIII during S. pyogenes infections in vivo 
Previous studies reported that the FXIII-mediated entrapment of S. pyogenes M1 bacteria 
within the fibrin network in vivo represents an early innate immune mechanism to retain 
invading bacteria at the site of infection. Thus, in a previously described subcutaneous 
S. pyogenes infection model leading to systemic infection and sepsis (Toppel et al., 2003), 
mice deficient in FXIII developed more severe signs of inflammation when compared with 
wild type animals (Loof et al., 2011b). Within the context of this PhD thesis, the impact of 
FXIII during skin infections caused by S. pyogenes of serotype M1 was investigated. To this 
end, the course of a S. pyogenes M1 skin and soft tissue infection in mice deficient in FXIII 
was compared with the infection in the corresponding wild type animals.  
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4.3.1 FXIII contributes to host defense against S. pyogenes at the site of 
infection in vivo 
As contact activation on the surface of pathogenic bacteria leads to the induction of the entire 
clotting cascade including FXIII in vitro (Loof et al., 2011b), the activation of FXIII at the site 
of infection was investigated in vivo. To this end, CBA wild type and FXIII-deficient mice were 
subcutaneously infected with S. pyogenes strain 5448 of serotype M1 and skin biopsies were 
prepared 24 h after bacterial inoculation for immunofluorescence microsocopy analysis 
(Figure 4.19). Skin biopsies from the local focus of infection were snap-frozen and stained by 
incubation with primary antibodies recognizing S. pyogenes or the activated form of murine 
and human FXIII (FXIIIa), respectively followed by fluorescence-conjugated secondary 
antibodies. As demonstrated in Figure 4.19, large amounts of bacteria were detected in skin 
samples of all groups of mice. Additionally, a widespread positive staining for FXIIIa in the 
same area in which the bacteria were located was detected in wild type mice (Figure 4.19, 
upper panel). As expected, no fluorescence signals for FXIIIa were observed in biopsies 
obtained from infected FXIII-deficient mice (Figure 4.19, middle panel). However, the staining 
for active FXIIIa was positive after infection of FXIII-deficient mice which were reconstituted 
with Fibrogammin after S. pyogenes M1 infection (Figure 4.19, lower panel). 
Consequently, these results lead to the suggestion that FXIII is activated at the site of 
S. pyogenes infection in wild type mice. The detection of FXIIIa in close proximity to 
S. pyogenes in wild type as well as in Fibrogammin-reconstituted FXIII-deficient mice 
indicated the participation of FXIII in the early innate immune response against S. pyogenes.  
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Figure 4.19:  FXIII activation at the site of S. pyogenes infection. 
Immunofluorescence microscopy analysis of skin biopsies obtained from infected wild 
type (upper panel), FXIII-deficient (middle panel), and FXIII-deficient mice 
reconstituted with Fibrogammin (Fg) (lower panel) 24h after bacterial inoculation. 
Samples were snap-frozen, sectioned, and stained for S. pyogenes (red) and 
activated FXIII (FXIIIa) (green). Cell nuclei were stained with DAPI (blue). The scale 
bars represent 10 µm. WT: wild type mice; FXIII-/-: FXIII-deficient mice. 
To further investigate the role of FXIII in the host defense against S. pyogenes skin 
infections, skin biopsies obtained from infected mice at 24 h after bacterial inoculation were 
additionally prepared for histopathological examination using HE staining. Whereas skin 
samples obtained from uninfected wild type (Figure 4.20 A) or FXIII-deficient mice (Figure 
4.20 B) show no signs of inflammation, samples from S. pyogenes-infected wild type mice 
exhibited moderate inflammation and mild dermatitis accompanied by edema, panniculitis 
and inflammation of the subcutis (Figure 4.20 C). In contrast, S. pyogenes caused severe 
necrotic dermatitis, severe panniculitis and extreme subcutaneous inflammation in FXIII-
deficient mice (Figure 4.20 D). Hence, the lack of FXIII might be responsible for the more 
severe skin inflammation observed in FXIII-deficient mice. This was additionally verified by 
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the attenuation in the inflammatory reaction of S. pyogenes-infected FXIII-deficient mice after 
exogenous reconstitution with the human FXIII-concentrate Fibrogammin (Fg; Figure 4.20 E). 
These observations clearly indicated a protective role for FXIII during early host defense 
against S. pyogenes mediated skin infections. 
 
Figure 4.20: Histological examination of the local focus of S. pyogenes infection. 
HE staining of representative skin sections from uninfected wild type (A) and FXIII-
deficient mice (B) as well as S. pyogenes-infected wild type (C), FXIII-deficient (D) and 
Fibrogammin-reconstituted FXIII-deficient (E) mice at 24 h after bacterial inoculation.  
E = edema, P = panniculitis, S = subcutaneous inflammation, N = necrosis. All scale 
bars represent 100 µm. 
4.3.2 FXIII-deficient mice developed a more severe systemic response to 
S. pyogenes skin infection 
As described above, an activation of FXIII was detected at the site of S. pyogenes infection 
24 h after bacterial inoculation (Figure 4.18). Due to the important role of FXIII in the contact 
system, the activated partial thromboplastin time (aPTT), as measurement of contact system 
A 
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activation, was determined in the plasma of infected wild type and FXIII-deficient mice at 
progressive times after subcutaneous inoculation of S. pyogenes (Figure 4.21). As a control, 
the aPTT was measured in the plasma of uninfected wild type and FXIII-deficient mice 
ranging between 30 and 40 s (Figure 4.21). The aPTT increased up to 50 to 60 s in both wild 
type and FXIII-deficient mice at 24 h after S. pyogenes inoculation. This moderate increase 
in the aPTT indicates an activation of the contact system that might explain the local 
activation of FXIII, which was detected at the same time of infection. While the aPTT 
decreased at 48 h of infection in wild type mice and further remains at normal levels, the 
aPTT increased progressively in FXIII-deficient mice, reaching approximately 90 s at 72 h of 
infection (Figure 4.21). An extreme prolongation of the aPTT was previously described to 
indicate a systemic contact activation which is connected with the development of sepsis and 
severe infections (Herwald et al., 2003; Oehmcke et al., 2009). Moreover, a recent report has 
shown that the degree of prolongation of the aPTT correlates with the severity of 
S. pyogenes infections (Fiebig et al., 2015). Therefore, the prolonged aPTT in infected FXIII-
deficient mice might be an indication of a more severe systemic infection. However, the 
aPTT in FXIII-deficient mice treated with Fibrogammin was comparable to that of infected 
wild type mice (Figure 4.21) supporting a role for FXIII in the modulation of contact activation 
during S. pyogenes skin infection. 
 
Figure 4.21: Activated partial thromboplastin time (aPTT) during S. pyogenes infection. 
The aPTT was measured in the plasma of wild type mice (black circles) and FXIII-
deficient mice (black squares) as well as FXIII-deficient mice which were reconstituted 
with Fibrogammin (white squares) after 24, 48 and 72 h of infection with S. pyogenes. 
Plasma obtained from uninfected wild type and FXIII-deficient mice served as control. 
The graph represents the mean ± SD of 3 to 9 mice per group obtained from three 
independent experiments. Statistical significance was calculated by ANOVA test:  *** p 
< 0.001. 
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To further examine the impact of FXIII in host defense to S. pyogenes skin infection, the level 
of the pro-inflammatory cytokine interleukin-6 (IL-6) was determined in the serum of wild type 
and FXIII-deficient mice at progressive times after bacterial inoculation (Figure 4.22). For this 
purpose, wild type and FXIII-deficient mice were subcutaneously infected with S. pyogenes 
5448 and the concentration of IL-6 was measured in the plasma obtained from infected mice 
by ELISA. While a moderated increase in the levels of IL-6 was measured in the plasma of 
all groups at 24 h of infection and remained at this moderated levels in wild type mice at 72 h 
of infection, a sharp increase in the level of the IL-6 level was observed in the plasma of 
FXIII-deficient mice at 72 h after bacterial inoculation (Figure 4.22). Interestingly, this 
increase in the plasma levels of IL-6 at 72 of infection was not observed after reconstitution 
of FXIII-deficient mice with Fibrogammin (Figure 4.22).  
 
Figure 4.22: IL-6 levels in the plasma of S. pyogenes-infected mice. 
Levels of IL-6 in the plasma of wild type (white bars), FXIII-deficient (black bars) and 
reconstituted FXIII-deficient (hatched bars) mice measured after 24 and 72 h of 
infection by ELISA. The graph represents the mean ± SD of 3 to 9 mice per group 
obtained from three independent experiments. Statistical significance was calculated 
by ANOVA test: ** p < 0.01, *** p < 0.001. 
Taken together, the results of the attenuated aPTT and moderate IL-6 production in the 
presence of FXIII (wild type and Fibrogammin-reconstituted FXIII-deficient mice) 
demonstrated a role for FXIII in the early innate immune response against S. pyogenes skin 
and soft tissue infections.  
4.3.3 FXIII reduces the systemic dissemination of S. pyogenes from the local 
site of infection 
To investigate a potential contribution of FXIII to limit bacterial spreading and systemic 
dissemination from the local site of infection at the skin, bacterial loads in blood, liver and 
spleen were determined in wild type and FXIII-deficient mice 72 h after subcutaneous 
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inoculation of S. pyogenes. Significant higher amounts of bacteria were detected in blood 
(Figure 4.23 A) and spleens (Figure 4.23 B) of FXIII-deficient mice compared to wild type 
mice. Bacterial loads were also higher in livers of mice deficient in FXIII, but no significant 
differences were recorded in comparison to wild type animals (Figure 4.23 C). However, 
bacterial loads in blood and spleens of FXIII-deficient mice which were reconstituted with 
Fibrogammin were significantly reduced when compared to untreated FXIII-deficient animals 
(Figure 4.23). The reconstitution with Fibrogammin leads also to a decreased amount of 
bacteria in the livers, but did not reach statistic significance. 
Taken together, these results indicate that FXIII contributed to the limitation of S. pyogenes 
systemic dissemination during skin infection. The FXIII-mediated entrapment of S. pyogenes 
at the site of infection may be the mechanism underlying this process. 
     
                  
Figure 4.23: Bacterial loads in blood and systemic organs of S. pyogenes-infected mice at 72 
h of infection. 
Wild type (black circles), FXIII-deficient (black squares) and reconstituted FXIII-
deficient mice (white squares) were infected with S. pyogenes 5448 and bacterial 
loads in blood (A), spleen (B) and liver (C) were determined after 72 h. The graphs 
represent the mean of 12 to 17 mice per group obtained from four independent 
experiments. Statistical significance was calculated by ANOVA test: * p < 0.05, ** p < 
0.01.   
A) 
B) C) 
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4.3.4 FXIII improves the survival of mice during S. pyogenes skin infection 
The beneficial role of FXIII during the early innate immune response against S. pyogenes 
skin infections was further investigated by recording the survival times of wild type, FXIII-
deficient and Fibrogammin-reconstituted FXIII-deficient mice after subcutaneous infection 
with S. pyogenes. Whereas approximately 70% of infected wild type mice survived after 7 
days of infection, 95% of FXIII-deficient mice succumbed to the infection (Figure 4.24 A). 
Reconstitution of FXIII-deficient mice with Fibrogammin improved the survival of these 
animals and only 10 % of the mice died by day 7 of infection (Figure 4.24 A). In addition, by 
day 6 of infection, the skin lesions of infected wild type mice were local and more superficial 
than the larger lesions associated with dermal necrosis and ulceration observed in FXIII-
deficient mice (Figure 4.24 B). Fibrogammin-treated FXIII-deficient mice developed small 
lesions comparable to those of wild type mice (Figure 4.24 B). 
 
Figure 4.24: Influence of FXIII in mouse survival and skin lesion severity. 
Infected wild type and FXIII-deficient mice as well as FXIII-deficient mice reconstituted 
with Fibrogammin were infected with S. pyogenes strain 5448 and the survival was 
monitored daily (A). Photographs show skin lesions of wild type (left panel), FXIII-
deficient (middle panel) and Fibrogammin-reconstituted FXIII-deficient mice (right 
panel) at day 6 of infection (B). The survival curves shown in (A) represent data from 
12 mice per group obtained from three independent experiments. 
A) 
B) 
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In summary, the results obtained from the survival studies indicate an important role of FXIII 
during S. pyogenes mediated skin infections. Thus, FXIII limited the development of a 
systemic immune response and bacterial spreading resulting in an improved survival of 
infected mice.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION 
88 
 
5 DISCUSSION 
During the last two decades, a growing body of evidence has been gathered demonstrating 
that coagulation is an integral part of the host innate immune response to pathogens 
(Delvaeye and Conway, 2009). Thus, contact activation was shown on the surface of gram-
positive bacteria such as S. pyogenes and S. aureus as well as on the surface of gram-
negative bacteria such as E. coli and Salmonella, leading to the induction of the entire 
clotting cascade including thrombin, fibrinogen and FXIII (Herwald et al., 2003; Loof et al., 
2011b). Already in 2004, Sun and colleagues proclaimed a critical role of fibrin clot formation 
during S. pyogenes infections by using a subcutaneous murine infection model (Sun et al., 
2004). Further studies reported that the activation of the contact system could lead to the 
immobilization of pathogenic bacteria, including S. pyogenes, within the newly formed fibrin 
network. Thus, the bacterial entrapment was proposed as a new innate immune mechanism 
to prevent bacterial spreading from the site of infection (Shannon et al., 2010; Wang et al., 
2010; Sun et al., 2009; Loof et al., 2011b). Coagulation FXIII was identified as a key factor 
that promotes the entrapment of pathogenic bacteria by cross-linking of bacterial surface 
structures with the fibrin network (Loof et al., 2011b; Wang et al., 2010).  Furthermore, it was 
demonstrated that FXIII targets the M1 protein on the surface of S. pyogenes enabling 
bacterial entrapment (Loof et al., 2011b). Previous studies postulated that the bacterial 
entrapment process is generally dependent of FXIII (Loof et al., 2011b; Wang et al., 2010). 
This hypothesis was supported by the observation that the gene encoding FXIII is highly 
conserved among the genome of vertebrates as well as invertebrates (Jiang and Doolittle, 
2003). Accordingly, FXIII represents the only coagulation factor that has homologues in the 
coagulation cascades of all species studied so far (Jiang and Doolittle, 2003; Loof et al., 
2011a).  
The main objective of this thesis was the investigation of the relevance of bacterial 
entrapment as an innate immune mechanism against streptococcal infections as well as the 
identification of key factors promoting this process. For this purpose, different bacterial 
species belonging to the genus Streptococcus were analyzed for their entrapment by in vitro 
clotting assays. The obtained experimental data demonstrated the efficient entrapment of 
S. pyogenes and SDSE. The entrapment of these bacteria was largely mediated by the 
expression of the M protein on the surface of S. pyogenes and of the M-like protein FOG on 
the surface of SDSE, as demonstrated by the reduced entrapment of these bacteria within 
fibrin networks when these surface proteins were lacking. In contrast to S. pyogenes and 
SDSE, no bacterial immobilization of S. pneumoniae and S. oralis was observed. These data 
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lead to the suggestion that the entrapment of bacteria within fibrin clots does not represent a 
mechanism of host defense against streptococcal infections in general but it is rather 
restricted to a few species. S. pyogenes of serotype M1 was selected for further studies 
because this bacterium can be efficiently immobilized within fibrin clots and, more interesting, 
this immobilization is influenced and enhanced by FXIII. Thus, the immobilization of 
S. pyogenes M1 was significantly reduced in FXIII-deficient plasma clots. The dependency of 
FXIII for bacterial immobilization was limited to S. pyogenes of M1 serotype since other 
serotypes such as M1-2, M3, M6, M49 and M53 were also entrapped within the fibrin clot but 
this entrapment was not affected by the presence/absence of FXIII. Further experiments 
using different S. pyogenes strains of serotype M1 and their corresponding M1 deficient 
mutant strains verified previous observations and confirmed the influence of FXIII and the M1 
protein on the entrapment of S. pyogenes M1 bacteria. 
During the entrapment, S. pyogenes M1 bacteria become cross-linked within the fibrin 
network by the action of FXIII. The detailed mechanism and type of interaction between FXIII 
and the M1 protein of S. pyogenes has not been elucidated yet. Initially, a covalent linkage 
between FXIII and the M1 protein (Loof et al., 2011b) was expected based on the 
enzymatic activity of FXIII as a transglutaminase catalyzing the formation of isopeptide bonds 
(Lorand and Graham, 2003). However, results obtained from experiments that were 
performed in the frame of this thesis rebutted a covalent linkage between FXIII and the M1 
protein that seems to represent more a recognition structure targeted by FXIII for bacterial 
entrapment. It is already known for a long time that M proteins bind fibrinogen (Tillett and 
Garner, 1933). Fibrinogen binding is mediated by the B repeat region of the M protein 
located within the semi-variable domain (Ringdahl et al., 2000). Fibrinogen also is the central 
factor of the coagulation cascade and represents the basic substance of the clot that ensures 
wound closure and prevents excessive blood loss after injury. Thrombin activates fibrinogen 
to fibrin that polymerizes into fibrin fibers. However, the formation of a stable fibrin network is 
mediated by FXIII-catalyzed cross-linking of fibrin molecules resulting in a stable clot. 
To get further insights into the molecular mechanisms underlying the interactions of 
fibrinogen, FXIII and the M1 protein, in vitro fibrinogen conversion experiments were 
performed. The findings of these experiments showed that, in the absence of FXIII, 
recombinant streptococcal M1 protein inhibited the conversion of fibrinogen into fibrin, which 
is required for bacterial entrapment. This inhibitory effect was an exclusive feature of the M1 
protein since it was not observed with recombinant M proteins of other serotypes or with the 
M-like protein FOG of SDSE. The inhibition of the fibrinogen conversion was also observed 
with whole S. pyogenes bacteria but only in case of serotype M1. Furthermore, deletion of 
the M1 protein in S. pyogenes resulted in loss of inhibition of fibrinogen conversion. These 
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findings supporting the ability of M1 proteins to interfere with fibrinogen conversion in the 
absence of FXIII are in good agreement with the findings showing that FXIII exclusively 
mediated the entrapment of S. pyogenes M1 bacteria. Taken together, the possibility to 
inhibit fibrin formation might represent a new mechanism of S. pyogenes serotype M1 
bacteria to prevent their entrapment by the coagulation system in the absence of FXIII.  
To broaden the knowledge about the molecular mechanism behind the inhibition of the fibrin 
formation by the M1 protein, fibrinogen conversion experiments using streptococcal M1 
protein constructs containing different M1 protein domains were performed. Interestingly, the 
A region of the M1 protein was identified to be responsible for the inhibition of the fibrinogen 
conversion. These results were confirmed by fibrinogen conversion experiments using 
heterologous expressed chimeric M1 and M3 proteins, whose A regions were exchanged, on 
the surface of L. lactis. Accordingly, the A1M3 protein, containing the A region of the M1 
protein inhibited the conversion of fibrinogen in the absence of FXIII whereas the A3M1 
protein which contains the A region of the M3 protein did not influence the fibrin formation. 
These experimental data supported the absolute requirement of the A region for inhibition of 
fibrinogen conversion by the M1 protein. Since the B repeats were described as the classical 
fibrinogen binding region of the M1 protein (Ringdahl et al., 2000), the identification of the A 
region as the domain of the M1 protein responsible for the inhibition of fibrinogen conversion 
was surprising. However, since the A region is located in the hypervariable region of the M 
proteins that highly differs in sequence and structure among the different M serotypes 
(Facklam et al., 1999), this could explain why this inhibitory mechanism is restricted to 
S. pyogenes of the M1 serotype.  
Despite the identification of the A region as the domain of the M1 protein that inhibits 
fibrinogen conversion, the exact mechanism behind this interaction is still unknown. 
Nevertheless, binding to fibrinogen may be assumed to be a precondition for inhibition of 
fibrinogen conversion. In this regard, Macheboeuf and colleagues identified a new cryptic 
fibrinogen binding site within the A region of the M1 protein (Macheboeuf et al., 2011). The 
capacity of the A region to bind fibrinogen was also demonstrated in this thesis by fibrinogen 
pulldown assays. Additionally, Macheboeuf et al. demonstrated that fibrinogen and the M1 
protein form a pathological network capable to activate neutrophils to release of critical 
amounts of the potent vasodilator heparin-binding protein (HBP) (Macheboeuf et al., 2011), 
which causes vascular leakage and tissue injury during STSS (Linder et al., 2009). As the 
inhibition of fibrinogen conversion by the M1 protein was not observed in the presence of 
FXIII, it can be speculated that FXIII might contribute to host defense by supporting bacterial 
entrapment after interfering with the capacity of S. pyogenes M1 to inhibit clot formation.  
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However, these considerations do not explain the mechanism behind the inhibition of 
fibrinogen conversion by the A region of the M1 protein. A potential inhibition of thrombin, the 
enzyme catalyzing the conversion of fibrinogen into fibrin, was discarded after demonstrating 
that thrombin was active in fibrinogen conversion experiments in the presence of the M1 
protein by using the chromogenic substrate S-2238 (data not shown). An alternative 
mechanism could be that the binding of fibrinogen to the A region of the M1 protein might 
lead to a conformational change within the fibrinogen molecule resulting in the inaccessibility 
of the thrombin cleavage sites on the fibrinogen molecule. Thrombin cleaves the 
fibrinopeptides A and B (FPA and FPB) from the fibrinogen α- and β-chains at arginine 
residues 16 and 14, respectively (Binnie and Lord, 1993). After cleavage of FPA and FPB, 
fibrin monomers polymerize to form fibrin fibers and networks. Further research addressing 
the structural analysis of fibrinogen bound to the A region in comparison to fibrinogen bound 
to the B repeat region of the M1 protein might help to clarify this hypothesis. 
Furthermore, the relevance of this inhibitory mechanism for the pathogenesis of S. pyogenes 
remains unclear, especially by considering the fact that this mechanism seems to be 
restricted to the serotype M1. This serotype is one of the most frequently appearing 
S. pyogenes strains worldwide causing invasive diseases (Steer et al., 2009). It can be 
speculated that the capacity of this bacteria to interfere with the clot formation and, thus, with 
the bacterial entrapment could contribute to the pathogenesis of this successful serotype. 
Binding of fibrinogen to the M protein to avoid the recognition of the bacteria by the host 
immune system has been proposed as an important strategy of S. pyogenes to resist 
phagocytosis (Whitnack et al., 1983; Horstmann et al., 1992). The potential contribution of 
the inhibition of fibrinogen conversion as mechanism to preserve intact fibrinogen on the 
bacterial surface and, thus, to resist phagocytosis by PMNs was also investigated. As the 
inhibition of fibrinogen conversion is a property of the M1 protein, the resistance to 
phagocytosis of L. lactis expressing M1 protein was compared with that of L. lactis 
expressing the M1 protein where the A region has been exchanged for that of the M3 protein 
(A3M1). However, no significant differences were observed in the resistance to phagocytosis 
of these two L. lactis strains (data not shown).  
In conclusion, the inhibition of the fibrinogen conversion by the M1 protein of S. pyogenes 
could prevent bacterial entrapment within a fibrin network at the site of infection and could 
promote the capacity of S. pyogenes to disseminate from local site of infection. Therefore, 
this mechanism could be used by S. pyogenes M1 for immunoevasion. However, this 
mechanism is only active in the absence of FXIII. This coagulation factor interferes with the 
inhibition of fibrinogen conversion and promotes the immobilization of S. pyogenes M1 within 
the fibrin clot. Thus, FXIII contributes to the early host defense against this pathogen. This 
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was previously demonstrated by Loof and colleagues (Loof et al., 2011b) by showing that 
mice lacking FXIII exhibited more severe signs of inflammation at the site of S. pyogenes 
infection when compared to wild type mice. A deeper investigation of the role played by FXIII 
in the host defense against S. pyogenes M1 skin infection was performed also in the frame of 
this thesis. 
After S. pyogenes invasion of the host, both the contact system and the innate immune 
components such as macrophages, DCs and PMNs are rapidly activated. Though 
coagulation is assumed to play a role during the very early phase of local infections, fibrin 
network formation and pathogen entrapment help to restrict the pathogen at the site of 
infection and to enable their fast elimination by the innate immune system. Thus, coagulation 
and especially the FXIII-mediated immobilization seems to play a major role during local skin 
and soft tissue infections caused by S. pyogenes of serotype M1. This hypothesis was 
supported by in vivo studies reporting that, after intravenous or intraperitoneal S. pyogenes 
administration, fibrin clot formation could not prevent the dissemination of S. pyogenes and 
the establishment of an infection (Sun et al., 2004; Shannon et al., 2010). In experiments 
performed in the frame of this thesis, wild type and FXIII-deficient mice were subcutaneously 
infected with the S. pyogenes strain 5448 of serotype M1T1. This globally disseminated 
subclone of the serotype M1T1 has been linked to the resurgence of severe invasive 
S. pyogenes infections observed since the 1980s in the western world and causes severe 
skin and soft tissue infections (Aziz and Kotb, 2008). Experimental data demonstrated that 
mice deficient in FXIII were much more susceptible to S. pyogenes M1-mediated skin 
infection than wild type mice as shown by the shorter survival times, the higher levels of 
bacterial dissemination from the local site of infection and the more intense systemic 
inflammation. In particular, FXIII-deficient mice exhibited higher levels of IL-6 at later times of 
infection and prolonged aPTT than wild type mice. Prolongation of aPTT is an indicator of 
contact activation that was also detected on the surface of S. pyogenes in vitro subsequently 
leading to the induction of the entire coagulation cascade (Loof et al., 2011b). Contact 
activation in vivo was also detected in human and mouse plasma after S. pyogenes infection 
(Sriskandan et al., 2000) and an extreme prolongation of this clotting parameter was 
observed during severe S. pyogenes infections (Herwald et al., 1998; Oehmcke et al., 2009). 
Indeed, abnormal systemic contact activation can lead to an overwhelming inflammation 
characterized by the release of massive amounts of vasoactive kinins such as BK that can 
contribute to the development of the most severe clinical outcomes of S. pyogenes infections 
such as sepsis and STSS (Oehmcke et al., 2009; Pixley et al., 1995; Henningham et al., 
2012). Thus, a careful regulation of coagulation is necessary during the innate immune 
response against S. pyogenes infection to maintain hemostasis under physiological levels.  
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The higher bacterial loads in blood and organs detected in mice deficient in FXIII when 
compared to wild type mice after 72 h of S. pyogenes skin inoculation support the concept 
that FXIII-mediated entrapment at the side of infection might prevent systemic dissemination 
of bacteria. As a proof of principle, FXIII-deficient mice reconstituted with Fibrogammin, a 
human FXIII concentrate that was subcutaneously administered after S. pyogenes infection, 
exhibited a reduced bacterial spreading in comparison to wild type mice and only moderate 
inflammation indicated by just slightly increased aPTT and IL-6 levels. Furthermore, FXIII-
reconstitution also improved the survival of FXIII-deficient mice after S. pyogenes infection to 
a rate that was even higher than the survival rates of wild type mice.  
Besides retention of bacteria at the site of infection to prevent their spreading by host 
coagulation, it has further been shown that bacteria are eliminated within the fibrin clot by 
antimicrobial activity. Thus, AMPs derived from components of the coagulation cascade, 
such as fibrinogen, thrombin and HK might promote the killing of entrapped bacteria 
(Påhlman et al., 2013; Frick et al., 2006; Papareddy et al., 2010; Nordahl et al., 2005). 
Furthermore, the killing of S. pyogenes and other fibrinogen-binding bacterial pathogens 
within thrombin activated human plasma was demonstrated (Loof et al., 2011b, Påhlman et 
al., 2013). These data suggest that within a fibrin clot AMPs reach effective concentrations to 
kill entrapped bacteria. 
In conclusion, the results of this thesis confirmed that FXIII exerts an important function in the 
early innate immune defense against skin infections caused by S. pyogenes bacteria of 
serotype M1. Upon coagulation activation in response to infection, activated FXIII was shown 
to target the M1 protein, which leads to the immobilization of bacteria within the fibrin 
network. In the absence of FXIII, the entrapment of S. pyogenes M1 bacteria is significantly 
reduced due to the inhibition of the conversion of fibrinogen to fibrin mediated by the M1 
protein. This ability might represent a novel virulence mechanism of S. pyogenes to avoid 
their entrapment and to promote bacterial dissemination in places where FXIII is absent. 
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6 FUTURE OUTLOOK 
The results of this thesis confirmed the protective role of FXIII during the early host defense 
against S. pyogenes of serotype M1 and support the concept of a potential therapeutic use of 
FXIII. However, the therapeutic potential of FXIII during S. pyogenes mediated infectious 
diseases needs to be further investigated. Since S. pyogenes bacteria have been shown to 
induce fibrinolysis by the secretion of streptokinase (SK) (Tillett and Garner, 1933; Green, 
1948), this pathogen might be able to use SK to escape from a fibrin clot. SK is a highly 
specific protein that activates human plasminogen to plasmin, the main protease of the 
fibrinolytic system (Danø et al., 1985; Marcum and Kline, 1983; Walker et al., 2005). 
Because SK is specific for human plasminogen and does not activate murine plasminogen, 
studies addressing the role of SK need to be performed with transgenic mice expressing 
human plasminogen (hPLG). These mice have been shown to be more susceptible to 
subcutaneously inoculated S. pyogenes bacteria when compared to wild type mice (Sun et 
al., 2004). The increased susceptibility is thought to be caused by the ability of S. pyogenes 
to induce fibrinolysis leading to an increased bacterial dissemination from the site of 
infection. However, an impact of FXIII during these interactions has not been demonstrated 
yet. Thus, infection experiments in which hPLG mice will be treated with Fibrogammin after 
inoculation of S. pyogenes might be a possibility to further investigate if FXIII could 
counteract or reduce SK-mediated fibrinolysis. However, SK was already identified as a 
target for the treatment of severe S. pyogenes infections and drugs that inhibit the production 
of SK have been shown to improve the survival of mice after bacterial inoculation (McArthur 
et al., 2012; Sun et al., 2012). Thus, a combination of both, the blockage of SK mediated 
fibrinolysis and the local increase of FXIII activity at the site of infection might be a concept 
for a more efficient treatment of S. pyogenes skin and soft tissue infections.  
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